

PRODUCT MONOGRAPH

^{Pr}**PROCYTOX**

Cyclophosphamide Tablets USP:
25 mg, 50 mg

Cyclophosphamide for injection:
200 mg, 500 mg, 1000 mg, 2000 mg (powder for injection) per vial

Antineoplastic Agent

Baxter Corporation
Mississauga, Ontario, L5N OC2

Date of Revision:
September 7, 2012

Submission Control No: 155509

Baxter and PROCYTOX are trademarks of Baxter International Inc., its subsidiaries or affiliates.

Table of Contents

PART I: HEALTH PROFESSIONAL INFORMATION.....	3
SUMMARY PRODUCT INFORMATION	3
INDICATIONS AND CLINICAL USE.....	3
CONTRAINDICATIONS	5
WARNINGS AND PRECAUTIONS.....	5
ADVERSE REACTIONS.....	13
DRUG INTERACTIONS	16
DOSAGE AND ADMINISTRATION	26
OVERDOSAGE	43
ACTION AND CLINICAL PHARMACOLOGY	44
STORAGE AND STABILITY	46
SPECIAL HANDLING INSTRUCTIONS	47
DOSAGE FORMS, COMPOSITION AND PACKAGING	48
PART II: SCIENTIFIC INFORMATION	50
PHARMACEUTICAL INFORMATION.....	50
DETAILED PHARMACOLOGY	50
TOXICOLOGY	51
REFERENCES	54
PART III: CONSUMER INFORMATION.....	63

PROCYTOX

Cyclophosphamide

PART I: HEALTH PROFESSIONAL INFORMATION

SUMMARY PRODUCT INFORMATION

Route of Administration	Dosage Form/Strength	Clinically Relevant Nonmedicinal Ingredients
Oral	Tablet: 25 mg, 50 mg	Tablet: Lactose
Intravenous	Powder for Injection: 200 mg, 500 mg, 1000 mg, 2000 mg per vial	<i>For a complete listing see Dosage Forms, Composition and Packaging section.</i> Injection: There are no nonmedicinal ingredients.

INDICATIONS AND CLINICAL USE

PROCYTOX (Cyclophosphamide), used alone or as a component of combination therapy is indicated for:

A: Frequently responsive myeloproliferative and lymphoproliferative disorders

1. **Malignant lymphomas** (See also **DOSAGE AND ADMINISTRATION**)
 - a) **Hodgkin's disease** [Cotswold stages II & III (massive mediastinal disease) and IIIA_{1,2} - IV E]
Non-Hodgkin's lymphomas (Working Formulation. Low Grade A,B,C; Intermediate Grade D,E,F,G; High Grade H,I,J)
 - b) Follicular lymphoma (B,C,D)
 - c) Lymphocytic lymphoma (A,B,E; mixed histiocytic, C,F)
** **Note:** Type A, small diffuse and well differentiated malignant lymphocytic lymphoma is consistent with chronic lymphocytic leukemia, to be considered a heterogenous group of chronic B-cell disorders.
 - d) Diffuse histiocytic lymphoma (G,H)
 - e) Lymphoblastic lymphoma (I)
 - f) Burkitt's lymphoma (J)

2. **Multiple Myelomas** (Myeloma stages II, IIIA, IIIB) (See also **DOSAGE AND ADMINISTRATION**)
3. **Leukemias** (See also **DOSAGE AND ADMINISTRATION**)
 - a) **Chronic Lymphocytic Leukemia (CLL)**
(Rai Stages II, III, IV) (Binet Stages B, C)
NOTE: Chronic lymphocytic leukemias are considered to be a heterogenous group of chronic B-cell disorders.
 - b) **Chronic Myelogenous Leukemia (CML)**
(Ineffective in acute blastic crises)
 - c) **Acute Myelogenous Leukemia (AML) (M0-M7)**
(Also called acute nonlymphocytic leukemia)
Acute Myelomonocytic Leukemia (AMML) (Type M4)
 - d) **Acute Lymphoblastic (Stem Cell) Leukemia (ALL) in children**
(Cyclophosphamide given during remission is effective in prolonging remission duration)
4. **Mycosis Fungoides (Advanced disease)** (Stages III, IVA, IVB) (See also **DOSAGE AND ADMINISTRATION**)

B: Frequently responsive solid malignancies (See also **DOSAGE AND ADMINISTRATION**)

1. **Neuroblastoma** (in patients with disseminated disease, Stage IV)
2. **Carcinoma of the Breast** (Stages II-IV)
3. **Retinoblastoma** (St.Jude Stages II-IV)

C: Malignant neoplasms of the lung (T N M Staging) (See also **DOSAGE AND ADMINISTRATION**)

Frequently responsive

Geriatrics (> 65 years of age): In elderly patients, monitoring for toxicities and the need for dose adjustment should reflect the higher frequency of decreased hepatic, renal, cardiac, or other organ function, and concomitant diseases or other drug therapy in this population.

Pediatrics (<16 years of age): Cyclophosphamide efficacy and safety have not been assessed in a registration trial.

CONTRAINDICATIONS

Cyclophosphamide is contraindicated in:

- Patients who have demonstrated hypersensitivity to this drug or its metabolites, alone or as part of combination chemotherapy
- Patients with urinary outflow obstructions
- Patients with severe myelosuppression
- Patients with severe renal impairment
- Patients with severe hepatic impairment
- Patients with an active infection, particularly *varicella zoster* infection
- Patients with severe immunosuppression

In combined chemotherapy regimen, the contraindications for each individual drug must be identified.

WARNINGS AND PRECAUTIONS

Serious Warnings and Precautions

- **PROCYTOX (Cyclophosphamide) is a potent drug and should be used only by physicians experienced with cancer chemotherapeutic drugs.**
- **Secondary Malignancy (see Warnings and Precautions).**
- **The patient's hematologic, hepatic and urinary profile must regularly be monitored.**
- **Acute cardiac toxicity after a single dose of cyclophosphamide (see Warnings and Precautions).**
- **Severe QT prolongation associated with ventricular tachyarrhythmia (see Warnings and Precautions).**
- **Hepatotoxicity(see Warnings and Precautions).**
- **Severe myelosuppression: Cyclophosphamide should not be administered to patients with a leukocyte count below 2500 cells/microliter (cells/ mm³) and/or a platelet count below 50,000 cells/microliter (cells/mm³) (see Warnings and Precautions).**
- **Urotoxicity (see Warnings and Precautions).**
- **Patients with renal impairment (see Warnings and Precautions).**
- **Acute pulmonary toxicity after a single dose of cyclophosphamide (see Warnings and Precautions).**
- **Fulminating anaphylaxis (with fatal outcome) (see Warnings and Precautions).**
- **Drug-drug interaction with depolarizing muscle relaxants causes inhibition of cholinesterase activity (see Drug-Drug Interactions section).**
- **Live vaccines may lead to vaccine-induced infection in patients on cyclophosphamide**

General

Risk factors for cyclophosphamide toxicities and their sequelae described here and in other sections may constitute contraindications if cyclophosphamide is not used for the treatment of a

life-threatening condition. In such situations, individual assessment of risk and expected benefits is necessary.

Prior to initiating treatment with PROCYTOX, it is necessary to exclude or correct any electrolyte imbalances.

Each individual component of a cyclophosphamide-containing poly-chemotherapy regimen must have its precaution profile reviewed.

Since cyclophosphamide is highly toxic with a relatively low therapeutic index, and a therapeutic response is not likely to occur without some evidence of toxicity, the drug must only be used under constant supervision of the attending physician.

Due to potential adverse effects of cyclophosphamide such as dizziness, blurred vision, visual impairment, nausea and vomiting which could be symptoms of vasomotor ataxia, caution should be advised when driving or operating machinery.

Alopecia occurs commonly in patients treated with even low doses of cyclophosphamide. With large parenteral doses, considerable hair loss (5-30%, with possible total alopecia) is to be expected. The hair can be expected to grow back after or even during continued treatment; it may, however be different in texture and/or colour.

If a patient who is to undergo surgery is receiving cyclophosphamide or has been treated with cyclophosphamide within 10 days of general anesthesia, the anesthetist should be so advised prior to surgery (See also **Drug-Drug Interactions section**).

In case of accidental paravenous administration of cyclophosphamide, the infusion should be stopped immediately, the extravascular cyclophosphamide solution should be aspirated with the cannula in place, and other measures should be instituted as appropriate.

Carcinogenesis and Mutagenesis

As with cytotoxic therapy in general, treatment with cyclophosphamide involves the risk of secondary tumours and their precursors as late sequelae.

The risk of developing urinary tract cancer as well as myelodysplastic alterations partly progressing to acute leukemias, or non-malignant disease in which immune processes are believed to be involved pathologically is increased. Other malignancies reported after use of cyclophosphamide or regimens with cyclophosphamide include lymphoma, thyroid cancer, and sarcomas.

In some cases, the second malignancy developed several years after cyclophosphamide treatment had been discontinued. Malignancy has also been reported after in utero exposure.

Urinary bladder malignancies have usually occurred in patients who previously had hemorrhagic cystitis. Animal studies demonstrate that the risk of bladder cancer can be markedly reduced by an adequate administration of mesna.

Cardiovascular

Myocarditis and myopericarditis, which may be accompanied by significant pericardial effusion and cardiac tamponade, have been reported with cyclophosphamide therapy and have led to severe, sometimes fatal congestive heart failure.

Histopathologic examination has primarily shown hemorrhagic myocarditis. Hemopericardium has occurred secondary to hemorrhagic myocarditis and myocardial necrosis.

Acute cardiac toxicity has been reported with a single dose of less than 20 mg/kg cyclophosphamide.

Following exposure to treatment regimens that included cyclophosphamide, supraventricular arrhythmias (including atrial fibrillation and flutter) as well as ventricular arrhythmias (including severe QT prolongation associated with ventricular tachyarrhythmia) have been reported in patients with and without other signs of cardiotoxicity.

The risk of cyclophosphamide cardiotoxicity may be increased following high doses of cyclophosphamide, in patients with advanced age, and in patients with previous radiation treatment of the cardiac region and/or previous or concomitant treatment with other cardiotoxic agents.

Particular caution is necessary in patients with risk factors for cardiotoxicity and in patients with pre-existing cardiac disease.

Endocrine and Metabolism

PROCYTOX has been shown to be more toxic in adrenalectomized dogs. Dose adjustments of PROCYTOX may be necessary for adrenalectomized patients.

Gastrointestinal

Administration of cyclophosphamide may cause nausea and vomiting.

Current guidelines on the use of antiemetics for prevention and amelioration of nausea and vomiting should be considered.

Alcohol consumption may increase cyclophosphamide-induced vomiting and nausea.

Administration of cyclophosphamide may cause stomatitis (oral mucositis).

Current guidelines on measures for prevention and amelioration of stomatitis should be considered.

Genitourinary

Prior to initiating treatment with PROCYTOX, it is necessary to exclude or correct any obstructions of the efferent urinary tract, cystitis, and infections.

Hemorrhagic cystitis, pyelitis, ureteritis, and hematuria have been reported with cyclophosphamide therapy. Bladder injury such as hemorrhagic cystitis/necrosis, fibrosis of the bladder and secondary cancer may develop in patients on long-term cyclophosphamide therapy. Should a cystitis in connection with micro- or macrohematuria appear during treatment with PROCYTOX, therapy must be interrupted until normalization.

Urotoxicity may mandate interruption or discontinuation of treatment.

Cystectomy may become necessary due to fibrosis, bleeding, or secondary malignancy.

Cases of urotoxicity with fatal outcomes have been reported.

Urotoxicity can occur with short-term and long-term use of cyclophosphamide. Hemorrhagic cystitis after single doses of cyclophosphamide has been reported.

Past or concomitant radiation or busulfan treatment may increase the risk for cyclophosphamide-induced hemorrhagic cystitis.

Secondary bacterial colonization of the initially abacterial cystitis may follow.

Urinary sediment should be checked regularly for the presence of erythrocytes and other signs of uro/nephrotoxicity. (See also **Monitoring and Laboratory Tests section**)

Cyclophosphamide should not be used in patients with active urinary tract infections.

Adequate treatment with mesna and/or strong hydration to force diuresis can markedly reduce the frequency and severity of bladder toxicity. It is important to ensure that patients empty the bladder at regular intervals.

Cyclophosphamide therapy should be discontinued in instances of severe hemorrhagic cystitis.

Cyclophosphamide has also been associated with nephrotoxicity, including renal tubular necrosis.

Hyponatremia associated with increased total body water, acute water intoxication, and cases of a syndrome resembling SIADH (syndrome of inappropriate secretion of antidiuretic hormone), including those with fatal outcome, have been reported in association with cyclophosphamide administration.

Hepatic/Biliary/Pancreatic

Veno-occlusive liver disease (VOLD) has been reported in patients receiving cyclophosphamide.

A cytoreductive regimen in preparation for bone marrow transplantation that consists of cyclophosphamide in combination with whole-body irradiation, busulfan, or other agents has been identified as a major risk factor for the development of VOLD. After cytoreductive therapy,

the clinical syndrome typically develops 1 to 2 weeks after transplantation and is characterized by sudden weight gain, painful hepatomegaly, ascites, and hyperbilirubinemia/jaundice.

VOLD has also been reported to develop gradually in patients receiving long-term low-dose immunosuppressive doses of cyclophosphamide.

As a complication of VOLD, hepatorenal syndrome and multiorgan failure may develop. Fatal outcome of cyclophosphamide-associated VOLD has been reported.

Risk factors predisposing a patient to the development of VOLD with high-dose cytoreductive therapy include

- preexisting disturbances of hepatic function,
- previous radiation therapy of the abdomen,
- low performance score.

The cytostatic effect of cyclophosphamide occurs after its activation, which takes place mainly in the liver.

Severe hepatic impairment may be associated with decreased activation of cyclophosphamide. This may alter the effectiveness of cyclophosphamide treatment and should be considered when selecting the dose and interpreting response to the dose selected. (See also **DOSAGE AND ADMINISTRATION**)

Immune

Treatment with PROCYTOX may cause myelosuppression and significant suppression of immune responses. Dose modification should be considered for patients who develop bacterial, fungal or viral infections in prior cycles. Patients with active infection should not be treated with PROCYTOX.

Cyclophosphamide-induced myelosuppression can cause leukopenia, neutropenia, thrombocytopenia (associated with a higher risk of bleeding events), and anemia.

Severe immunosuppression has led to serious, sometimes fatal, infections. Sepsis and septic shock have also been reported. Infections reported with cyclophosphamide include pneumonias, as well as other bacterial, fungal, viral, protozoal, and parasitic infections.

Latent infections can be reactivated. Reactivation has been reported for various bacterial, fungal, viral, protozoal, and parasitic infections.

Live vaccines should not be administered to immunocompromised patients.

Antimicrobial prophylaxis may be indicated in certain cases of neutropenia at the discretion of the managing physician.

In case of neutropenic fever, antibiotics and/or antimycotics must be given.

Caution is indicated, when administering cyclophosphamide to patients with tumor cell infiltration of bone marrow (see **DOSAGE and ADMINISTRATION**).

Cyclophosphamide should not be administered to patients with a leukocyte count below 2500 cells/microliter (cells/mm³) and/or a platelet count below 50,000 cells/microliter (cells/mm³).

The fall in the peripheral blood cell and thrombocyte count and the time taken to recover may increase with increasing doses of cyclophosphamide.

The nadirs of the reduction in leukocyte count and thrombocyte count are usually reached in weeks 1 and 2 of treatment. The levels of peripheral blood cell counts normalize after approximately 20 days.

Severe myelosuppression must be expected particularly in patients pretreated with and/or receiving concomitant chemotherapy and/or radiation therapy.

Peri-Operative Considerations

Cyclophosphamide may interfere with normal wound healing.

Renal

In patients with renal impairment, particularly in patients with severe renal impairment, decreased renal excretion may result in increased plasma levels of cyclophosphamide and its metabolites. This may result in increased toxicity and should be considered when determining the dosage in such patients. (See also **DOSAGE AND ADMINISTRATION**)

Respiratory

Pneumonitis and pulmonary fibrosis have been reported during and following treatment with cyclophosphamide. Pulmonary veno-occlusive disease and other forms of pulmonary toxicity have also been reported. Pulmonary toxicity leading to respiratory failure has been reported. Prognosis for affected patients is poor.

Late onset of pneumonitis (greater than 6 months after start of cyclophosphamide) appears to be associated with a particularly high mortality. Pneumonitis may develop even years after treatment with cyclophosphamide.

Acute pulmonary toxicity has been reported after a single cyclophosphamide dose.

Sensitivity/Resistance

Anaphylactic reactions including those with fatal outcomes have been reported in association with cyclophosphamide.

Possible cross-sensitivity with other alkylating agents has been reported.

Sexual Function/Reproduction

Cyclophosphamide is genotoxic and mutagenic, both in somatic and in male and female germ cells. Therefore, women should not become pregnant and men should not father a child during therapy with cyclophosphamide.

Men should not father a child for at least 6 months after the end of therapy.

Animal data indicate that exposure of oocytes during follicular development may result in a decreased rate of implantations and viable pregnancies, and in an increased risk of malformations. This effect should be considered in case of intended fertilization or pregnancy after discontinuation of cyclophosphamide therapy. The exact duration of follicular development in humans is not known, but may be longer than 12 months.

Sexually active women and men should therefore use effective methods of contraception.

Cyclophosphamide interferes with oogenesis and spermatogenesis. It may cause sterility in both sexes.

Development of sterility appears to depend on the dose of cyclophosphamide, duration of therapy, and the state of gonadal function at the time of treatment.

Cyclophosphamide-induced sterility may be irreversible in some patients.

Female patients

Amenorrhea, transient or permanent, associated with decreased estrogen and increased gonadotropin secretion develops in a significant proportion of women treated with cyclophosphamide.

For older women, in particular, amenorrhea may be permanent.

Oligomenorrhea has also been reported in association with cyclophosphamide treatment.

Girls treated with cyclophosphamide who have retained ovarian function after completing treatment are at increased risk of developing premature menopause (cessation of menses before age of 40 years).

Male patients

Men treated with cyclophosphamide may develop oligospermia or azospermia, which are normally associated with increased gonadotropin but normal testosterone secretion.

Boys treated with cyclophosphamide during prepubescence may develop secondary sexual characteristics normally, but may have oligospermia or azospermia.

Some degree of testicular atrophy may occur.

Cyclophosphamide-induced azospermia is reversible in some patients, though the reversibility may not occur for several years after cessation of therapy.

Special Populations

Pregnant Women:

Cyclophosphamide crosses the placental barrier. Treatment with cyclophosphamide has a genotoxic effect and may cause fetal damage when administered to pregnant women.

Malformations have been reported in children born to mothers treated with cyclophosphamide during the first trimester of pregnancy.

Exposure to cyclophosphamide in utero may cause miscarriage, fetal growth retardation, and fetotoxic effects manifesting in the newborn, including leukopenia, anemia, pancytopenia, severe bone marrow hypoplasia, and gastroenteritis.

Animal data suggest that an increased risk of failed pregnancy and malformations may persist after discontinuation of cyclophosphamide.

If cyclophosphamide is used during pregnancy, or if the patient becomes pregnant while taking this drug or after treatment, the patient should be apprised of the potential hazard to a fetus.

Nursing Women:

Cyclophosphamide is passed into the breast milk. Neutropenia, thrombocytopenia, low hemoglobin, and diarrhea have been reported in children breast fed by women treated with cyclophosphamide. Women must not breastfeed during treatment with cyclophosphamide.

Pediatrics (<16 years of age): PROCYTOX has not been studied in children.

Geriatrics (> 65 years of age): While age-related renal and/or hepatic impairment may require cautious dose adjustment, no geriatrics-specific problems are expected to limit the usefulness of PROCYTOX in the elderly.

Monitoring and Laboratory Tests

During treatment, the patient's hematologic profile (particularly neutrophils and platelets) should be monitored regularly, to determine the degree of hematopoietic suppression.

Leukocyte counts must be conducted regularly during treatment: at intervals of 5-7 days when starting treatment and every 2 days if the counts drop below 3000/mm³. Daily counts may be necessary under certain circumstances. In patients receiving long-term treatment, counts every two weeks are usually sufficient. If signs of myelosuppression become evident, it is recommended to check the red blood count and the platelet count. Platelet count and hemoglobin value should be obtained prior to each administration and at appropriate intervals after administration. Urinary sediment should also be checked regularly for the presence of erythrocytes and other signs of uro/nephrotoxicity.

Urine should be examined regularly for red cells, a possible indicator for hemorrhagic cystitis.

Frequent liver function tests (LFT's) and periodic monitoring of electrolytes are advised.

Because cyclophosphamide is associated with pneumonitis and pulmonary fibrosis, monitoring of PFT's should be considered.

Due to potential QT-interval prolongation, periodic EKG's are recommended.

ADVERSE REACTIONS

Adverse Drug Reaction Overview

Increased risk for and severity of pneumonias (including fatal outcomes), reactivation of latent infections, malignant and benign neoplasms, progression of underlying malignancies (including fatal outcomes), different degrees of myelosuppression (sometimes with life threatening infections), leucopenia, anemia, thrombocytopenia, fulminating anaphylaxis (with fatal outcome), hypersensitivity reactions, syndrome of inappropriate antidiuretic hormone secretion, tumor lysis syndrome, hematuria, confusion, neurotoxicity (both the central and peripheral nervous system), cardiotoxicity (with fatal outcomes), hearing disorders, arterial and venous occlusive disorders with and without embolization, gastrointestinal hemorrhages, acute pancreatitis, hepatotoxicity, hepatitis, toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema multiforme, skin eruption, hemorrhagic cystitis, rhabdomyolysis, sterility in both sexes, fetal malformation and toxicity (including intra-uterine death), multiorgan failure, general physical deterioration, increased lactate dehydrogenase and C-reactive protein.

NOTE: Many side effects of cancer chemotherapy are unavoidable, since they represent the drug's pharmacologic action. Leukopenia and thrombocytopenia are used as guidelines, among others, to aid in individual dosage titration.

Clinical Trial Adverse Drug Reactions

The list of adverse reactions to cyclophosphamide in this document is based on postmarketing data.

Post-Market Adverse Drug Reactions

The following is a summary of adverse reactions reported with cyclophosphamide either alone or in combination with other chemotherapeutic agents in the post marketing experience, listed by MedDRA system Organ Class (SOC), then by Preferred Term in order of severity, where feasible. In the case of a polychemotherapy regimen, the adverse reaction profile of each drug component should be reviewed.

INFECTIONS AND INFESTATIONS:

The following manifestations have been associated with myelosuppression and immunosuppression caused by cyclophosphamide: increased risk for and severity of pneumonias (including fatal outcomes), other bacterial, fungal, viral, protozoal, parasitic infections; reactivation of latent infections, including viral hepatitis, tuberculosis, JC virus with progressive multifocal leukoencephalopathy (including fatal outcomes), *Pneumocystis jiroveci*, herpes zoster, *Strongyloides*, Sepsis and Septic shock (including fatal outcomes)

NEOPLASMS, BENIGN AND MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS):

Acute leukemia (Acute myeloid leukemia, Acute promyelocytic leukemia), Myelodysplastic syndrome, Lymphoma (Non-Hodgkin's lymphoma), Sarcomas, Renal cell carcinoma, Renal pelvis cancer, Bladder cancer, Ureteric cancer, Thyroid cancer, Treatment related secondary malignancy, Carcinogenic effect in offspring, Tumor lysis syndrome. Additionally, progression of underlying malignancies, including fatal outcomes, have been reported.

BLOOD AND LYMPHATIC SYSTEM DISORDERS:

Myelosuppression manifested as Bone marrow failure, Pancytopenia, Neutropenia, Agranulocytosis, Granulocytopenia, Thrombocytopenia (complicated by bleeding), Leukopenia, Anemia; Febrile neutropenia, Lymphopenia, Disseminated intravascular coagulation, Hemolytic uremic syndrome (with thrombotic microangiopathy), Hemoglobin decreased

IMMUNE SYSTEM DISORDERS:

Immunosuppression, Anaphylactic shock, Anaphylactic/Anaphylactoid reaction (including fatal outcomes), Hypersensitivity reaction

ENDOCRINE DISORDERS:

Water intoxication, Syndrome of inappropriate antidiuretic hormone secretion (SIADH) with fatal outcomes.

METABOLISM AND NUTRITION DISORDERS:

Hyponatremia with fatal outcomes, Fluid retention, Anorexia, Blood glucose increased, Blood glucose decreased, tumor lysis manifested by hyperkalemia, hyperuricemia

PSYCHIATRIC DISORDERS:

Confusional state

NERVOUS SYSTEM DISORDERS:

Encephalopathy, Convulsion, Dizziness, Neurotoxicity has been reported and manifested as Reversible posterior leukoencephalopathy syndrome, Myelopathy, Peripheral neuropathy, Polyneuropathy, Neuralgia, Dysesthesia, Hypoesthesia, Paresthesia, Tremor, Dysgeusia, Hypogeusia, Parosmia

EYE DISORDERS:

Blurring of Vision, Myopia, Visual impairment, Conjunctivitis, Lacrimation increased

EAR AND LABYRINTH DISORDERS:

Deafness, Hearing impaired, Tinnitus

CARDIAC DISORDERS:

Cardiac arrest, Ventricular fibrillation, Ventricular tachycardia, Cardiogenic shock, Pericardial effusion (progressing to cardiac tamponade), Myocardial hemorrhage, Myocardial infarction, Cardiac failure congestive (including fatal outcomes), Cardiac failure (including fatal outcomes),

Left ventricular failure, Left ventricular dysfunction, Cardiomyopathy, Myocarditis, Pericarditis, Carditis, Atrial fibrillation, Supraventricular arrhythmia, Ventricular arrhythmia, Bradycardia, Tachycardia, Palpitations, Electrocardiogram QT prolonged, Ejection fraction decreased

VASCULAR DISORDERS:

Pulmonary embolism, Venous thrombosis, Vasculitis, Peripheral ischemia, Hypertension, Hypotension, Flushing, Hot flush, Blood pressure decreased.

RESPIRATORY, THORACIC, AND MEDIASTINAL DISORDERS:

Pulmonary veno-occlusive disease, Acute respiratory distress syndrome, Interstitial lung disease as manifested by Pulmonary fibrosis, Respiratory failure (including fatal outcomes), Obliterative bronchiolitis, Organizing pneumonia, Alveolitis allergic, Pneumonitis; Respiratory distress, Pulmonary hypertension, Pulmonary edema, Pleural effusion, Bronchospasm, Dyspnea, Hypoxia, Cough, Nasal congestion, Nasal discomfort, Oropharyngeal pain, Rhinorrhea, Sneezing

GASTROINTESTINAL DISORDERS:

Enterocolitis hemorrhagic, Gastrointestinal hemorrhage, Acute pancreatitis, Colitis, Enteritis, Cecitis, Mucosal ulceration, Stomatitis, Diarrhea, Vomiting, Constipation (sometimes severe), Nausea, Abdominal pain, Abdominal discomfort, Parotid gland inflammation.

HEPATOBIILIARY DISORDERS:

Veno-occlusive liver disease with fatal outcomes, Cholestatic hepatitis, Cytolytic hepatitis, Hepatitis, Cholestasis; Hepatotoxicity with Hepatic failure, Hepatic encephalopathy, Ascites, Hepatomegaly, Jaundice, Blood bilirubin increased, Hepatic function abnormal, Hepatic enzymes increased (Aspartate aminotransferase increased, Alanine aminotransferase increased, Blood alkaline phosphatase increased, Gamma-glutamyltransferase increased)

SKIN AND SUBCUTANEOUS TISSUE DISORDERS:

Toxic epidermal necrolysis, Stevens-Johnson syndrome, Erythema multiforme, Palmar-plantar erythrodysesthesia syndrome, Radiation recall dermatitis, Toxic skin eruption, Urticaria, Dermatitis, Rash, Blister, Pruritus, Erythema, Skin discoloration, Nail discoloration, Nail disorder, Alopecia (See WARNINGS AND PRECAUTIONS), Facial Swelling, Hyperhidrosis

MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS:

Rhabdomyolysis, Scleroderma, Muscle spasms, Myalgia, Arthralgia

RENAL AND URINARY DISORDERS:

Renal failure, Renal tubular necrosis, Renal tubular disorder, Renal impairment, Nephropathy toxic, Hemorrhagic cystitis resulting in death, Hemorrhagic ureteritis, Bladder necrosis, Cystitis ulcerative, Bladder fibrosis, Bladder contracture, Hematuria, Nephrogenic diabetes insipidus, Cystitis, Atypical urinary bladder epithelial cells, Blood creatinine increased, Blood urea nitrogen increased

PREGNANCY, PUERPERIUM, AND PERINATAL CONDITIONS:

Premature labor

REPRODUCTIVE SYSTEM AND BREAST DISORDERS:

Infertility, Ovarian failure (atrophy, fibrosis and complete absence of follicular structure), Ovarian disorder, Ovulation disorder, Amenorrhea, Oligomenorrhea, Testicular atrophy, Azoospermia, Oligospermia, Blood estrogen decreased, Blood gonadotrophin increased

CONGENITAL, FAMILIAL AND GENETIC DISORDERS:

Intra-uterine death, Fetal malformation, Fetal growth retardation, Fetal toxicity (including myelosuppression, gastroenteritis)

GENERAL DISORDERS AND ADMINISTRATIVE SITE:

Multiorgan failure, General physical deterioration, Influenza-like illness, Injection/infusion site reactions (thrombosis, necrosis, phlebitis, inflammation, pain, swelling, erythema), Pyrexia, Edema, Chest pain, Mucosal inflammation, Asthenia, Pain, Chills, Fatigue, Malaise, Headache

INVESTIGATIONS:

Blood lactate dehydrogenase increased, C-reactive protein increased

DRUG INTERACTIONS

Overview

Cyclophosphamide is administered as an inactive prodrug that must undergo activation to form the active metabolite 4 hydroxy cyclophosphamide through phase I metabolism by cytochrome P450 (CYP) enzymes 2B6, 2C8, 2C9, 2C19, 3A4 and 3A5. Detoxification is primarily through glutathione S transferases (GSTA1, GSTP1) and alcohol dehydrogenase (ALDH1, ALDH3). Concomitant therapy with inducers of cyclophosphamide metabolizing enzymes (e.g. CYP 2B6, 2C9, 3A4) enhances the enzyme expression and may potentially increase the formation of metabolites responsible for cytotoxicity. In contrast, the inhibitors could interfere with cyclophosphamide activation and may alter the effectiveness of cyclophosphamide treatment.

Genetic polymorphism in the drug metabolizing enzymes CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1, ALDH3A1 do not explain the inter individual variability in cyclophosphamide and 4 hydroxy cyclophosphamide pharmacokinetics. Renal impairment might increase the risk of toxicity due to increase in plasma level of cyclophosphamide and its metabolites. Severe hepatic impairment would decrease activation of cyclophosphamide.

In some patients, alcohol may increase cyclophosphamide-induced vomiting and nausea.

A reduced antitumor activity was observed in tumor-bearing animals during ethanol (alcohol) consumption and concomitant oral low-dose cyclophosphamide medication.

Planned coadministration or sequential administration of other substances or treatments that could increase the likelihood or severity of toxic effects (by means of pharmacodynamic or pharmacokinetic interactions) requires careful individual assessment of the expected benefit and

the risks. Patients being treated with cyclophosphamide and agents that reduce its activation should be monitored for a potential reduction of therapeutic effectiveness and the need for dose adjustment.

Drug- Drug Interactions

It is prudent to monitor, among others, the following drugs if administered concurrent with cyclophosphamide: Colchicine, Probenecid, Sulfapyridine, Chlorambucil, Mercaptopurine,

Combined or sequential use of cyclophosphamide and other agents with similar toxicities can cause combined (increased) toxic effects.

Potential Drug-Drug Interactions

<u>Name/Class/Category</u>	<u>Ref</u>	<u>Effect</u>	<u>Clinical Comment</u>
<u>Inducers of human hepatic and extrahepatic microsomal enzymes* (e.g., cytochrome P450 enzymes)</u> Benzodiazepines, Carbamazepine, Chloral hydrate, Corticosteroids, Phenobarbital, Phenytoin, Rifampin	L	An increase of the concentration of cytotoxic metabolites may occur with inducers of CYP enzymes.	The potential for hepatic and extrahepatic microsomal enzyme induction must be considered in case of prior or concomitant treatment with substances known to induce an increased activity of such enzymes. Patients receiving such combinations must be monitored closely for signs of toxicity to permit timely intervention.
<u>Inhibitors of CYP isoforms*</u> Aprepitant, Bupropion, Busulfan, Ciprofloxacin, Chloramphenicol, Fluconazole, Itraconazole, Prasugrel, Sulfonamides, Thiotepa	L	These substances may delay/reduce activation of cyclophosphamide. Reduced activation of cyclophosphamide may alter the effectiveness of cyclophosphamide treatment.	Patients receiving such combinations must be monitored closely for signs of toxicity to permit timely intervention.

<u>Name/Class/Category</u>	<u>Ref</u>	<u>Effect</u>	<u>Clinical Comment</u>
ACE inhibitors	L	Increased hematotoxicity and/or immunosuppression may result from a combined effect of cyclophosphamide and ACE inhibitors. ACE inhibitors can cause leukopenia. Pancytopenia is a known ADR of the combination of cyclophosphamide and ACE-inhibitors.	Patients receiving such combinations must be monitored closely for signs of toxicity to permit timely intervention.
Allopurinol	L	Concurrent cyclophosphamide with allopurinol may enhance the bone marrow toxicity of cyclophosphamide.	If concurrent use is unavoidable, frequent monitoring for toxic effects is strongly recommended.
Amiodarone	L	Increased pulmonary toxicity may result from a combined effect of cyclophosphamide and amiodarone	Patients receiving such combinations must be monitored closely for signs of toxicity to permit timely intervention.
Amphotericin B	L	Increased nephrotoxicity may result from a combined effect of cyclophosphamide and amphotericin B	Patients receiving such combinations must be monitored closely for signs of toxicity to permit timely intervention.
Anthracyclines	L	Increased cardiotoxicity may result from a combined effect of cyclophosphamide and anthracyclines.	Patients receiving such combinations must be monitored closely for signs of toxicity to permit timely intervention.
Azathioprine	L	Increased risk of hepatotoxicity (liver necrosis)	Patients receiving such combinations must be monitored closely for signs of toxicity to permit timely intervention.

<u>Name/Class/Category</u>	<u>Ref</u>	<u>Effect</u>	<u>Clinical Comment</u>
Bupropion	L	Cyclophosphamide metabolism by CYP2B6 may inhibit bupropion metabolism.	Patients receiving such combinations must be monitored closely for signs of toxicity to permit timely intervention.
Busulfan	L	Increased incidence of hepatic veno-occlusive disease and mucositis. Cyclophosphamide clearance has been reported to be reduced and half-life prolonged in patients who receive high-dose cyclophosphamide less than 24 hours after high-dose busulfan.	Patients receiving such combinations must be monitored closely for signs of toxicity to permit timely intervention.
Cimetidine	L	An increase of the concentration of cytotoxic metabolites may occur.	Patients receiving such combinations must be monitored closely for signs of toxicity to permit timely intervention.
Ciprofloxacin	L	When given prior to the treatment with cyclophosphamide (used for conditioning prior to bone marrow transplantation), ciprofloxacin has been reported to result in a relapse of the underlying disease and reduced cyclophosphamide effectiveness.	Patients receiving such combinations must be monitored closely for signs of toxicity to permit timely intervention.

<u>Name/Class/Category</u>	<u>Ref</u>	<u>Effect</u>	<u>Clinical Comment</u>
Coumarins	L	Both increased and decreased warfarin effect have been reported in patients receiving warfarin and cyclophosphamide.	Patients receiving such combinations must be monitored closely for signs of toxicity to permit timely intervention.
Cyclosporine	L	Lower serum concentrations of cyclosporine have been observed in patients receiving a combination of cyclophosphamide and cyclosporine than in patients receiving only cyclosporine.	This interaction may result in an increased incidence of graft-versus-host disease. Patients receiving such combinations must be monitored closely for signs of toxicity to permit timely intervention.
Cytarabine	L	Increased cardiotoxicity may result from a combined effect of cyclophosphamide and cytarabine.	Patients receiving such combinations must be monitored closely for signs of toxicity to permit timely intervention.
Depolarizing muscle relaxants (e.g., succinylcholine)	L	Cyclophosphamide treatment causes a marked and persistent inhibition of cholinesterase activity. Prolonged apnea may occur with concurrent depolarizing muscle relaxants	If a patient has been treated with cyclophosphamide within 10 days of general anesthesia, the anesthesiologist should be alerted. Patients receiving such combinations must be monitored closely for signs of toxicity to permit timely intervention.
Digoxin (e.g., β -acetyldigoxin)	L	Cytotoxic treatment has been reported to impair intestinal absorption of digoxin.	Patients receiving such combinations must be monitored closely for signs of toxicity to permit timely intervention.
Disulfiram	L	An increase of the concentration of cytotoxic metabolites may occur.	Patients receiving such combinations must be monitored closely for signs of toxicity to permit timely intervention.

Name/Class/Category	Ref	Effect	Clinical Comment
Etanercept	L	Cyclophosphamide used concomitantly with Etanercept was associated with a higher incidence of non-cutaneous solid malignancies.	Patients receiving such combinations must be monitored closely for signs of toxicity to permit timely intervention.
G-CSF, GM-CSF (granulocyte colony-stimulating factor, granulocyte macrophage colony-stimulating factor)	L	Reports suggest an increased risk of pulmonary toxicity in patients treated with cytotoxic chemotherapy that includes cyclophosphamide and G-CSF or GMCSF.	Patients receiving such combinations must be monitored closely for signs of toxicity to permit timely intervention.
Glyceraldehyde	L	An increase of the concentration of cytotoxic metabolites may occur with glyceraldehyde.	Patients receiving such combinations must be monitored closely for signs of toxicity to permit timely intervention.
Indomethacin	L	Cyclophosphamide use concomitantly with indomethacin may cause severe pulmonary edema and acute life-threatening water intoxication.	Appropriate supportive measures should be employed if water intoxication occurs. Patients receiving such combinations must be monitored closely for signs of toxicity to permit timely intervention.
Irradiation of the cardiac region	L	Increased cardiotoxicity may result from a combined effect of cyclophosphamide and irradiation of the cardiac region.	Patients receiving such combinations must be monitored closely for signs of toxicity to permit timely intervention.

<u>Name/Class/Category</u>	<u>Ref</u>	<u>Effect</u>	<u>Clinical Comment</u>
Lovastatin	L	Concurrent use in cardiac transplant patients of cyclophosphamide with the antihyperlipidemic HMG-CoA reductase inhibitor lovastatin may be associated with an increased risk of rhabdomyolysis and acute renal failure.	Patients receiving such combinations must be monitored closely for signs of toxicity to permit timely intervention.
Methotrexate	L	Concurrent administration of methotrexate and cyclophosphamide may result in the inhibition of the metabolism of cyclophosphamide.	Patients receiving such combinations must be monitored closely for signs of toxicity to permit timely intervention.
Metronidazole	L	Acute encephalopathy has been reported in a patient receiving cyclophosphamide and metronidazole.	Causal association is unclear. In an animal study, the combination of cyclophosphamide with metronidazole was associated with increased cyclophosphamide toxicity. Patients receiving such combinations must be monitored closely for signs of toxicity to permit timely intervention.
Natalizumab	L	Increased hematotoxicity and/or immunosuppression may result from a combined effect of cyclophosphamide and natalizumab.	Patients receiving such combinations must be monitored closely for signs of toxicity to permit timely intervention.

<u>Name/Class/Category</u>	<u>Ref</u>	<u>Effect</u>	<u>Clinical Comment</u>
Ondansetron	L	There have been reports of a pharmacokinetic interaction between ondansetron and high-dose cyclophosphamide resulting in decreased cyclophosphamide AUC.	Patients receiving such combinations must be monitored closely for signs of toxicity to permit timely intervention.
Paclitaxel	L	Increased hematotoxicity and/or immunosuppression may result from a combined effect of cyclophosphamide and paclitaxel. Increased hematotoxicity has been reported when cyclophosphamide was administered after paclitaxel infusion.	Patients receiving such combinations must be monitored closely for signs of toxicity to permit timely intervention.
Pentostatin	L	Increased cardiotoxicity may result from a combined effect of cyclophosphamide and pentostatin.	Patients receiving such combinations must be monitored closely for signs of toxicity to permit timely intervention.

<u>Name/Class/Category</u>	<u>Ref</u>	<u>Effect</u>	<u>Clinical Comment</u>
Phenobarbitone	L	Concomitant use of cyclophosphamide and phenobarbitone resulted in cyclophosphamide half-life decreased from 4.3 hours to 1.6 hours. In another study, cyclophosphamide biotransformation was increased 2 to 3 fold after phenobarbitone. In these studies, urinary excretion of metabolites over 48 hours was unchanged.	Patients receiving such combinations must be monitored closely for signs of toxicity to permit timely intervention.
Prednisone	L	Cyclophosphamide use concomitantly with prednisone may cause a fatal acute respiratory failure.	Patients receiving such combinations must be monitored closely for signs of toxicity to permit timely intervention.
Protease Inhibitors	L	Concomitant use of protease inhibitors may increase the concentration of cytotoxic metabolites. Increased incidence of mucositis.	Use of protease inhibitor-based regimens was found to be associated with a higher incidence of infections and neutropenia in patients receiving cyclophosphamide, doxorubicin, and etoposide (CDE) than use of a Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)-based regimen. Patients receiving such combinations must be monitored closely for signs of toxicity to permit timely intervention.
Sulfonyl ureas	L	The blood glucose-lowering effect of sulfonyl ureas may be intensified when administered concomitantly with cyclophosphamide.	Patients receiving such combinations must be monitored closely for signs of toxicity to permit timely intervention.

<u>Name/Class/Category</u>	<u>Ref</u>	<u>Effect</u>	<u>Clinical Comment</u>
Tamoxifen	L	Concomitant use of tamoxifen and chemotherapy (including cyclophosphamide) may increase the risk of thromboembolic complications.	Patients receiving such combinations must be monitored closely for signs of toxicity to permit timely intervention.
Thiazide diuretics (e.g. hydrochlorothiazide)	L	Increased hematotoxicity and/or immunosuppression may result from a combined effect of cyclophosphamide and thiazide diuretics.	Patients receiving such combinations must be monitored closely for signs of toxicity to permit timely intervention.
Trastuzumab	L	Increased cardiotoxicity may result from a combined effect of cyclophosphamide and trastuzumab.	Patients receiving such combinations must be monitored closely for signs of toxicity to permit timely intervention.
Vaccines	L	The immunosuppressive effects of cyclophosphamide can be expected to reduce the response to vaccination. Use of live vaccines may lead to vaccine-induced infection.	Patients receiving such combinations must be monitored closely for signs of toxicity to permit timely intervention.
Verapamil	L	Cytotoxic treatment has been reported to impair intestinal absorption of orally administered verapamil	Patients receiving such combinations must be monitored closely for signs of toxicity to permit timely intervention.

<u>Name/Class/Category</u>	<u>Ref</u>	<u>Effect</u>	<u>Clinical Comment</u>
Zidovudine	L	Increased hematotoxicity and/or immunosuppression may result from a combined effect of cyclophosphamide and zidovudine.	Patients receiving such combinations must be monitored closely for signs of toxicity to permit timely intervention.

* This list provides some representative examples and is not an exhaustive list.

Legend: L = Literature

Drug-Food Interactions

Concomitant administration of grapefruit or grapefruit juice is not recommended since grapefruit contains a compound that may impair the activation of cyclophosphamide, and thereby its efficacy.

Drug-Herb Interactions

Inducers of human hepatic and extrahepatic microsomal enzymes (e.g., cytochrome P450 enzymes): The potential for increased formation of metabolites responsible for cytotoxicity and other toxicities (depending on the enzymes induced) must be considered in case of prior or concomitant treatment with, for example:

- St. John's wort

Drug-Laboratory Interactions

The following laboratory alterations have been reported in the literature and are potentially clinically significant:

Positive reactions may be suppressed:

- Candida skin test
- Mumps skin test
- Trichophyton skin test
- Tuberculin PPD skin test

False-positive results may be produced:

- Papanicolaou (PAP) test

Serum concentrations may be decreased:

- Pseudocholinesterase

Blood and urine concentrations may be increased:

- Uric acid

DOSAGE AND ADMINISTRATION

Dosing Considerations

Cyclophosphamide should be administered only by physicians experienced with this drug.

Dosage must be individualized

- Doses and duration of treatment and/or treatment intervals depend on the therapeutic indication, the scheme of a combination therapy, the patient's general state of health and organ function, and the results of laboratory monitoring (in particular, blood cell monitoring). In combination with other cytostatics of similar toxicity, a dose reduction or extension of the therapy-free intervals may be necessary. Use of hematopoiesis stimulating agents (colony-stimulating factors and erythropoiesis stimulating agents) may be considered to reduce the risk of myelosuppressive complications and/or help facilitate the delivery of the intended dosing.

During or immediately after the administration, adequate amounts of fluid should be ingested or infused to force diuresis in order to reduce the risk of urinary tract toxicity. Therefore, cyclophosphamide should be administered in the morning. Prophylactic treatment with mesna is recommended for protection of the bladder

Activation of cyclophosphamide requires hepatic metabolism; therefore, oral and intravenous administrations are preferred.

Patients with Hepatic Impairment (See **WARNINGS AND PRECAUTIONS**)

Patients with Renal Impairment (See **WARNINGS AND PRECAUTIONS**)

Patients requiring dialysis

- Cyclophosphamide and its metabolites are dialyzable, although there may be differences in clearance depending upon the dialysis system being used. In patients requiring dialysis, use of a consistent interval between cyclophosphamide administration and dialysis should be considered.

Recommended Dose and Dosage Adjustment

INITIAL LOADING DOSE: PROCYTOX

Patients with normal hematologic and bone marrow function:

Adults: i.v. 40-50 mg/Kg (1.5-1.8 g/m²) as 10 to 20 mg/Kg/day for 2-5 days
Children: i.v. 2 - 8 mg/Kg (60-250 mg/m²) in divided doses for six or more days

Patients with compromised bone marrow function due to prior radiation therapy, poly-chemotherapy, or tumour cell infiltration, must have their initial loading dose reduced by 30-50%. Dosage adjustment must also be considered for children and adults with concurrent disease or special conditions.

Adults: p.o. 1-5 mg/Kg/day depending upon the tolerance of the patient
Children: p.o. 2-8 mg/Kg (60-250 mg/m²) in divided doses for six or more days

Morning administration of PROCYTOX is recommended.

The leukocyte count generally serves as a guide to dosage adjustments, and maintaining a range of 2500-4000 cells/mm³ is recommended to possibly avoid infection.

The above initial loading doses may lead to transient or more persistent reduction to 200 cells/mm³. **The patient's hematologic profile must carefully be monitored.**

MAINTENANCE DOSE: PROCYTOX

It is generally advisable to administer the largest maintenance dose that can reasonably be tolerated by the patient, unless the disease is unusually sensitive to cyclophosphamide.

Adults:

i.v.	10-15 mg/Kg (350-550 mg/m ²) every 7-10 days
i.v.	3- 5 mg/Kg (110-185 mg/m ²) twice weekly
p.o.	1- 5 mg/Kg/day

Children:

i.v.	10-15 mg/Kg every 7-10 days, or 30 mg/Kg at three- to four-week intervals or when bone marrow recovery occurs.
p.o.	2- 5 mg/Kg (50-150 mg/m ²) twice weekly

Concurrent disease, special conditions including performance index must lead to dosage adjustment.

COMBINATION CHEMOTHERAPY REGIMEN

NOTE: These recommendations are not based on Phase III registration trials. Due to constant new developments in cancer chemotherapy, the following presentation can only be viewed as an example of effective treatments. Treatment centre-specific dose and schedule variations, addition of surgery, irradiation and other treatment modalities were not included; descriptions of treatment regimens involving chemotherapy with cyclophosphamide alone or as component of combination chemotherapy is the focus of this presentation.

When deciding upon a particular treatment regimen, the literature cited in this section must carefully be reviewed.

As with monotherapy, it is advisable that treatment-related emergency measures and equipment, including pathology-specific antibiotics be physically present during combination chemotherapy.

It should be noted that regular and high-dose cyclophosphamide as monotherapy or as component of polychemotherapy are being effectively used in patients resistant to first line treatment such as melphalan or busulfan. Objective responses in a variety of different forms of cancer, plus its relative platelet-sparing effect make cyclophosphamide an alternate drug of choice. Cyclophosphamide as 60 mg/Kg i.v. for 2 days may be administered for bone marrow

transplant conditioning. In patients with multiple transfusions, cyclophosphamide is not adequately IMMUNOSUPPRESSIVE, requiring the addition of AT to the retransplant cytoreduction conditioning.

Administration

HODGKIN'S DISEASE:

***Patients with relapsed Hodgkin's disease and presenting marrow abnormality*^{10,43}**

C Cyclophosphamide 1.5 g/m² i.v. daily for 4 consecutive days

B Carmustine (BCNU) 300 mg/m² i.v. for 1 day

V Etoposide (VP-16) 100-125 mg/m² i.v. b.i.d. for 3 consecutive days

PSCT Autologous peripheral stem cell transplantation i.v. following **CBV** administration: All blood products were irradiated prior to use. Mesna or continuous bladder irrigation was used to prevent hemorrhagic cystitis.

***Patients with relapsed Hodgkin's disease*⁷⁸**

C Cyclophosphamide 1.5 g/m² i.v. daily (days -6 to -3)

B Carmustine(BCNU) 300 mg/m² i.v. for 1 day (day -6)

V Etoposide (VP-16) 125 mg/m² i.v. b.i.d. (days -6 to -4)

ABMT Autologous bone marrow transplantation i.v. on day 0, 3 days after end of chemotherapy

rhG-CSF 60 µg/Kg/day (Continuous increase or decrease of AGC = Absolute granulocyte count requires dose adjustment of rhG-CSF) for a maximum of 28 days, beginning on day 1

Note: For this treatment regimen, all patients received 1 day prior to commencement of chemotherapy 1.0 g oral phenytoin sodium, followed by 300 mg daily for 4 days as prophylaxis against seizures.

***Patients with resistant relapsed Hodgkin's disease*⁴⁷**

C Cyclophosphamide 1.5 g/m² i.v. daily (days 1-4)

B Carmustine (BCNU) 300 mg/m² i.v. on day 1

V Etoposide (VP-16) 150 mg/m² i.v. daily (days 1-3)

ABMT Autologous bone marrow transplantation on day 7

***Patients with resistant relapsed Hodgkin's disease*⁴⁷**

C Cyclophosphamide 3.0 g/m² i.v. days 1 and 2

B Carmustine (BCNU) 200 mg/m² i.v. days 1-4

V Etoposide (VP-16) 250 mg/m² i.v. days 1-4

ABMT Autologous bone marrow transplantation on day 7

***Patients with resistant relapsed Hodgkin's disease*⁴⁷**

C Cyclophosphamide 1.8 g/m² i.v. daily (days 1-4)

B Carmustine (BCNU) 600 mg/m² i.v. on day 5

V Etoposide (VP-16) 400 mg/m² i.v. b.i.d. (days 1-3)

ABMT Autologous bone marrow transplantation on day 7
(With/without radiation therapy)

Patients with resistant relapsed Hodgkin's disease⁶⁷

- C** Cyclophosphamide 1.8 g/m² i.v. daily (days -7 to -4)
B Carmustine(BCNU) 600 mg/m² i.v. on day -3
V Etoposide(VP-16) 400 mg/m² i.v. b.i.d. (days -7 to -4)
ABMT Autologous bone marrow transplant on day 0.

Patients with refractory Hodgkin's disease and non-Hodgkin's lymphoma⁸⁴
(Maximum-tolerated dose = MTD)

- C** Cyclophosphamide 0.9 g/m² i.v. b.i.d. (days -7 to -4)
B Carmustine(BCNU) 450 mg/m² i.v. bolus on day -7
V Etoposide(VP-16) 250 mg/m² i.v. b.i.d. (days -7 to -4)
ABMT Unpurged autologous bone marrow transplant

Other treatments for Hodgkin's disease containing cyclophosphamide

CVPP⁵⁹

- C** Cyclophosphamide 300 mg/m² i.v. on days 1 and 8
V Vinblastine 10 mg/m² i.v. on days 1, 8 and 15
P Procarbazine 100 mg/m² p.o. on days 1 to 15
P Prednisone 40 mg/m² p.o. on days 1 to 15

NOTE: Repeat the cycle every 28 days. Prednisone is given in cycles 1 and 4 only

14-year follow-up results:

CVPP²⁴

- C** Cyclophosphamide 300 mg/m² i.v. on days 1 and 8
V Vinblastine 10 mg/m² i.v. on days 1, 8, and 15
P Procarbazine 100 mg/m² p.o. on days 1 to 15
P Prednisone 40 mg/m² p.o. on days 1 to 15 (**Cycles 1 and 4 only**)

NOTE: Repeat cycles every 42 days for a minimum of six cycles. Patients in CR after 6 or more cycles of CVPP continue to receive CVPP at 2-4- month intervals as maintenance therapy for a median period of 34 months.

NON-HODGKIN'S LYMPHOMA

Since the acute risks of multi-agent systemic chemotherapy include myelosuppression, possible hemorrhage, and infection, use of transplantation of bone marrow, peripheral stem cell support, various colony-stimulating factors^{76,81} and pathology-specific antibiotics should be considered prior to chemotherapy, to speed up the patient's recovery.

Childhood NHL (Lymphoblastic and non-lymphoblastic lymphoma)^{22,80}

Induction phase of modified LSA₂-L₂

- Cyclophosphamide 1.2 g/m² i.v. day 1
Vincristine 2.0 mg/m² i.v. (maximum dose 2.0 mg) days 3, 10, 17, and 24
Methotrexate 6.25 mg/m² i.v. days 5, 31, and 34
Daunomycin 60 mg/m² i.v. days 12 and 13
Prednisone 60 mg/m² p.o. (maximum dose 60 mg/m²) days 3-30

COMP Induction

Cyclophosphamide	1.2 g/m ² i.v. day 1
Vincristine	2.0 mg/m ² i.v. (maximum dose, 2.0 mg) days 3, 10, 17, and 24
Methotrexate	6.25 mg/m ² i.th. days 5, 31, and 34
Methotrexate	300 mg/m ² i.v. (60% of dose as i.v. push, 40% as 4-h infusion on day 12)
Prednisone	60 mg/m ² p.o. (maximum dose 60 mg) days 3-30

COMP Maintenance

Cyclophosphamide	1 g/m ² i.v. day 1
Vincristine	1.5 g/m ² (maximum dose 2.0 mg) i.v. days 1 and 4
Methotrexate	6.25 mg/m ² i.th. day 1 (excluded from first maintenance cycle)
Methotrexate	300 mg/m ² i.v. (60% of dose as i.v. push, 40% as 4-h infusion) on day 15
Prednisone	60 mg/m ² p.o. (maximum dose 60 mg) days 1-5 (excluded from first maintenance cycle)

NOTE: Repeat maintenance cycle every 28 days

Adult advanced-stage intermediate- or high-grade Non-Hodgkin's lymphomas:

CHOP^{22,28,29,30,38}

C	Cyclophosphamide	750 mg/m ² i.v. on day 1
H	Hydroxydaunorubicin (Doxorubicin)	50 mg/m ² i.v. on day 1
O	Oncovin (Vincristine)	1.5 mg/m ² i.v. (max. 2 mg/m ²) on day 1
P	Prednisone	100 mg/m ² p.o. on days 1 to 5

In a large phase III comparison of CHOP vs. third-generation regimens (m-BACOD, ProMACE-CytaBOM, MACOP-B), CHOP resulted in similar failure-free and overall survival rates with lower severe toxicity.³⁰

LNH-84 Induction phase

Doxorubicin	75 mg/m ² i.v. on day 1
Cyclophosphamide	1.2 g/m ² i.v. on day 1
Vindesine	2 mg/m ² i.v. on days 1 and 5
Bleomycin	10 mg <i>p.o.</i> on days 1 and 5
Methylprednisolone	60 mg/m ² on days 1 and 5
Methotrexate	12 mg i.th. once per course

NOTE: Courses are given every 15 days, or when polymorphonuclear neutrophils exceed 1500/ μ L. Total therapy (induction followed by consolidation and final intensification course) requires 8 months.

F-MACHOP^{2,37}

Vincristine	0.5 mg/m ² i.v. at time 0 and at 12 hours on day 1
Cyclophosphamide	800 mg/m ² i.v. at 36 hours (i.e., middle of day 2)
5-Fluorouracil	15 mg/Kg continuous i.v. infusion starting at 36 hours for 6 hours
Cytarabine	1 g/m ² by continuous i.v. infusion for 6 hours immediately following 5-FU infusion
Doxorubicin	60 mg/m ² i.v. at 48 hours (end of day 2)

Methotrexate	500 mg/m ² by continuous i.v. infusion for 6 hours beginning at hour 60 (middle of day 3)
Prednisone	60 mg/m ² orally from day 1 to day 14
Leucovorin	20 mg/m ² i.v. 18 hours after methotrexate infusion, and repeated every 12 hours for four doses

NOTE: Prophylactic **i.th.** methotrexate, 12 mg total dose, plus cytarabine, 30 mg/m² is given to patients considered at high risk of CNS infiltration (advanced stage, marrow involvement, less than 30 years of age) on day 10 of each course. A course is administered every 3 or 4 weeks for a total of 6 cycles. During the last three cycles, the dose of doxorubicin is reduced to 40 mg/m² and that of methotrexate to 300 mg/m².

PRO-MACE-CYTABOM^{22,28,30}

Cyclophosphamide	650 mg/m ² i.v. on day 1
Doxorubicin	25 mg/m ² i.v. on day 1
Etoposide	120 mg/m ² i.v. over 60-minutes on day 1
Prednisone	60 mg/m ² p.o. on days 1 to 14
Cytarabine	300 mg/m ² i.v. on day 8
Bleomycin	5 mg/m ² i.v. on day 8
Vincristine	1.4 mg/m ² i.v. on day 8
Methotrexate	120 mg/m ² i.v. on day 8
Leucovorin rescue	25 mg/m ² orally every 6 hours for four doses beginning on day 9

NOTE: Since this regimen is associated with an increased incidence of interstitial pneumonia with four related deaths reported, all patients now receive prophylactic trimethoprim-sulfamethoxazole as 2 tablets or 1 double-strength tablet twice daily.

NOTE: The next cycle begins on day 22. At least 6 cycles, two cycles beyond a complete remission are given.

PRO-MACE-CYTABOM chemotherapy is reported to produce at least 84% complete response (CR) in adult patients with diffuse aggressive lymphoma. The corresponding relapse rate (RR) is reported in these patients as 25%. The percentage of long-term survival is given as 69% after a 4.5-month duration of treatment.

COP-BLAM⁶¹

Cyclophosphamide	500 mg/m ² continuous i.v. infusion on day 1
Doxorubicin	50 mg/m ² continuous i.v. infusion on day 1
Vincristine	1 mg/m ² i.v. days 1-10
Prednisolone	40 mg/m ² p.o. days 1-10
Procarbazine	100 mg/m ² p.o. days 1-10
Bleomycin	10 mg/person continuous i.v. infusion on day 14
Lenograstim*	2µg/Kg/day s.c. when granulocyte count <1000 x 10 ⁹ /L

Mean duration of administration of G-CSF for this trial was 5.4 days

* Glycosylated recombinant human G-CSF

NOTE: This regimen was repeated 6 times every 21 days

NOTE: Full dose of drugs for ≤ 70 years

80% of full dose of cyclophosphamide and doxorubicin for ages 71-75

70% of full dose of cyclophosphamide and doxorubicin for ages 76-79

60% of full dose of cyclophosphamide and doxorubicin for ages 79-83

Localized low grade lymphoma (Working Formulation "B"):

Risk-adapted **COP/CHOP-Bleo** combined modality⁷⁴

Cyclophosphamide 1000 mg/m² i.v. on day 1

Vincristine 1.4 mg/m² i.v.(max. 2.0mg) on day 1

Bleomycin 15 units total i.v. on day 1

Prednisone 60 mg/m² **p.o.** daily for 5 days

Patients with extranodal involvement, bulky disease (≥ 5cm), or LDH↑:

In addition to the above COP-Bleo

Doxorubicin 50 mg/m² i.v. (max.450 mg/m² or less if cardiac toxicity) on day 1

Cyclophosphamide↓ 750 mg/m² i.v. on day 1

NOTE: Bleomycin was not given to patients >60 years old, or to those with existing pulmonary toxicity. Therapy-related pulmonary toxicity led to removal of bleomycin. Both cyclophosphamide and doxorubicin were reduced by 20% following abdominal radiation.

NOTE: COP/CHOP-Bleo for 3 cycles Initial chemotherapy IF(Involved field) radiotherapy to supradiaphragmatic fields at a rate of 2 Gy per fraction to a total of 40 Gy in 4 weeks.

COP/CHOP-Bleo for 7 cycles to a total of 10 cycles.

MULTIPLE MYELOMAS²⁸

CYP + PRED

Cyclophosphamide 150 to 250 mg/m² (500 mg maximum) i.v. **or** p.o. per week

Prednisone 100 mg **p.o.** every other day.

M-2 (VMBCP)^{29,57}

Vincristine 0.03 mg/Kg i.v. on day 1

Carmustine 0.5 mg/Kg i.v. on day 1

Cyclophosphamide 10 mg/Kg i.v. on day 1

Melphalan 0.25 mg/Kg **p.o.** for 4 days

Prednisone 1.0 mg/Kg/day **p.o.** for 7 days, and then 0.5 mg/Kg/day **p.o.** for 7 days

NOTE: Repeat the cycle every 35 days

VMCP alternating with VCAP

V M C P

Vincristine 1.0 mg/m² (maximum 1.5 mg) i.v. on day 1

Melphalan 6 mg/m² **p.o.** on days 1 to 4

Cyclophosphamide 125 mg/m² **p.o.** on days 1 to 4

Prednisone 60 mg/m² **p.o.** on days 1 to 4

NOTE: Alternate every 3 weeks with the V C A P regimen

V C A P

Vincristine	1.0 mg/m ² (maximum 1.5 mg) i.v. on day 1
Cyclophosphamide	125 mg/m ² p.o. on days 1 to 4
Doxorubicin	30 mg/m ² i.v. on day 1
Prednisone	60 mg/m ² p.o. on days 1 to 4

Salvage treatment for VAD-resistant multiple myeloma:**HyperCVAD²³**

Cyclophosphamide 300 mg/m² (over 3 hrs) b.i.d. days 1 to 3 (total 1.8 g/m²) with at least 2 L oral fluids. Simultaneously, continuous infusion of 600 mg/m²/day mesna for 3 days.

12 hours after completion of cyclophosphamide:

Vincristine	2.0 mg continuous infusion over 48 hours
Doxorubicin	50 mg/m ² continuous infusion over 48 hours

Day 11:

Vincristine	2.0 mg rapid i.v. injection
Dexamethasone	20 mg/m ² p.o. as single morning dose for 5 days beginning on day 1, and for 4 days beginning on day 11
G-CSF	5 µg/Kg/day s.c. starting on day 6, to be repeated daily until granulocyte level >2000/µL

Between days 8 and 18:

Ciprofloxacin	500 mg p.o. b.i.d.
Fluconazole	100 mg p.o. daily
Acyclovir	300 mg p.o. t.i.d.

NOTE: Patients received a second cycle of **HyperCVAD**, provided there had been a 50% reduction in myeloma protein.

Maintenance for responding patients:

Cyclophosphamide	125 mg/m ² p.o. b.i.d. for 5 days every 5 weeks
Dexamethasone	20 mg/m ² each morning for 5 days every 5 weeks

NOTE: Myeloablative treatment with autologous blood stem cell transplantation may be needed for persistent resistant disease or remission consolidation.

High-dose cyclophosphamide + GCS-F → PBPC ↑ /Multiple myeloma³⁵

Hour	Cyclophosphamide(CP)	Mesna
-30 min		20% of total dose of CP as 30 min infusion
0 h		1 g/m ² (1 h infusion) Same total dose of CP, continuous infusion over 24 hrs
2 h	1 g/m ² (1 h infusion)	
4 h	1 g/m ² (1 h infusion)	
6 h	1 g/m ² (1 h infusion)	
8 h	1 g/m ² (1 h infusion)	
10 h	1 g/m ² (1 h infusion)	

CVP

Cyclophosphamide 400mg/m² p.o. on days 1 to 5
 Vincristine 1.4 mg/m² i.v. on day 1
 Prednisone 100 mg/m² p.o. on days 1 to 5

CHOP

C Cyclophosphamide 750 mg/m² i.v. on day 1
H Doxorubicin (Hydroxydaunorubicin) 50 mg/m² i.v. on day 1
O Vincristine (Oncovin) 1.4 mg/m² i.v. on day 1
P Prednisone 100 mg² p.o. on days 1 to 5

COP

Cyclophosphamide 400 mg/m² i.v. on day 1
 Vincristine 1.0 mg/m² i.v. on day 1
 Prednisone 40 mg/m² p.o. on days 1 to 10

Chronic Myelogenous Leukemia (CML)²²

(Ineffective in acute blastic crises)

NOTE: For patients under 50 years of age with an HLA-identical sibling, consider an allogeneic bone marrow transplant in the chronic phase.

Acute Myelogenous Leukemia (AML) (M0-M7) ²²

Most centers suggest marrow transplantation for patients who have an appropriately matched HLA-compatible allogeneic sibling donor. Autologous marrow transplantation provides a potential transplant option for patients who lack a histocompatible donor. Whether ABMT offers an advantage over chemotherapy alone in children with AML in first remission is currently being assessed. DNA damage and repair in patients receiving high-dose (60 mg/Kg in the evenings of days 8 and 7 before transplant) cyclophosphamide and radiation(2 Gy TBI in the morning of days 5 to 0) must be assessed,³¹ to obtain a safe interval between cyclophosphamide and irradiation.

Acute Lymphoblastic (Stem Cell) Leukemia (ALL) in Children⁶⁸

(Cyclophosphamide given during remission is effective in prolonging remission duration)

Adult Acute Lymphoblastic Leukemia (ALL)**Induction with additional options:**

Prednisone 40-60 mg/m²/day p.o. for 21 days
 Vincristine 1.4 mg/m² i.v. days 1, 8, 15, and 22
 Daunorubicin 45 mg/m²/day i.v. on days 1-3 or days 16-18
 Cyclophosphamide 1 g/m² i.v. on day 1
 L-Asparaginase 5000 IU/m²/day i.m. for 10-14 days or 10000 IU/m² s.c. weekly for 3 weeks
 Cytarabine (ara-C) 1-3 g/m² i.v. over 4-6 hours and given every 12 hours for 4-8 doses

Maintenance Course C of the French Multicentre Study (PAME):

Etoposide	200 mg/m ² i.v. on day 1
Cyclophosphamide	600 mg/m ² i.v. on day 1
Prednisone	40 mg/m ² /day p.o. on days 15 to 21
6-Mercaptopurine	50 mg/m ² /day p.o. on days 15 to 21

Reinduction Phase II of a German Multistudy Group:

Cyclophosphamide	650 mg/m ² (maximum 1000 mg) i.v. on day 29
Cytarabine	75 mg/m ² i.v. on days 31 to 34 and 38 to 41
Thioguanine	60 mg/m ² p.o. on days 29 to 34

MYCOSIS FUNGOIDES (Advanced disease, Stages III, IVA, IVB)

Combined topical and systemic therapy after initial conservative topical treatment failed⁴²:

Total electron-beam radiation therapy, using rotating dual fields of between 3000 to 3200 cGy total dose to the skin for 8 to 12 weeks (skin tolerance). During the above therapy, the following 21-day cycles of parenteral combination chemotherapy were added:

Cyclophosphamide	500 mg/m ² i.v. on day 1
Doxorubicin	50 mg/m ² i.v. on day 1
Etoposide	100 mg/m ² i.v. on days 1 to 3
Vincristine	1.4 mg/m ² (maximum 2 mg) i.v. on day 1

NOTE: A total of 8 cycles for patients with stage III and IVA A total of 16 cycles for patients with stage IVB (visceral disease), doxorubicin was omitted from the regimen after a cumulative dose of 450 mg/m² was reached, and cyclophosphamide was then increased to 750 mg/m²

Other treatment combinations in addition to topical therapy:

(In advanced disease, the polychemotherapy addition may not significantly improve the outcome)

CHOP, COP, CVP (See pp. 31 for regimen detail)

FREQUENTLY RESPONSIVE SOLID MALIGNANCIES**NEUROBLASTOMA (In patients with disseminated disease, Stages III, IV & IV.S)**

Combination chemotherapy regimen (myeloablative therapy included) with or without surgery and/or radiation therapy in children with disseminated neuroblastoma, included cyclophosphamide for both BMT conditioning and as regimen component, vincristine, doxorubicin, cisplatin, melphalan, vindesine, etoposide, teniposide and rescue with either allogeneic or autologous bone marrow.

The **CVD** regimen (cyclophosphamide, vincristine, dacarbazine) has been found active in advanced neuroblastoma, producing responses in 80% of children with metastatic disease.⁴ It should be noted that, based upon the neuroblastoma results, the **CVD** regimen has successfully been used in the treatment of advanced, malignant pheochromocytoma after optimization of antihypertensive therapy. Treatment strategy comparison was made, based upon the recognition that both tumours are neuroendocrine with similar clinical and biologic characteristics.

Treatment of neuroblastoma with intraspinal extension (NBL 90/SIOP):⁶⁴

4 alternating courses (AB) prior to surgery (removal of dumbbell neuroblastoma tumour), and 2 alternating courses postoperatively: Each course once every 21 days

Course A:

Carboplatin 200 mg/m² i.v. per day x 3 days
Etoposide (VP-16) 150 mg/m² i.v. per day x 3 days

Course B:

Cyclophosphamide 300 mg/m² p.o. or i.v. per day x 5 days
Vincristine 1.5 (max 2.0 mg) mg/m² i.v. per day on days 1 and 5
Doxorubicin 60 mg/m² i.v. on day 5

Neuroblastoma CVD and CVDD regimen:²⁷

Cyclophosphamide 750 mg/m² i.v. on day 1
Vincristine 1.5 mg/m² i.v. on day 5 (maximum dose 2.0 mg)
Dacarbazine (DTIC) 250 mg/m²/day i.v. days 1 to 5

NOTE: This regimen was repeated every 22 days whenever possible.

Cyclophosphamide 750 mg/m² i.v. on day 1
Vincristine 1.5 mg/m² i.v. on day 5 (maximum dose 2.0 mg)
Dacarbazine (DTIC) 200 mg/m²/day i.v. days 1-5
Doxorubicin (adriamycin) 40 mg/m² i.v. on day 3

NOTE: This regimen was repeated every 29 days whenever possible. Dose escalations for both cyclophosphamide and dacarbazine were allowed for.

OPEC⁷⁵

Vincristine 1.5 mg/m² i.v. bolus on day 0
Cyclophosphamide 600 mg/m² i.v. bolus on day 0
Cisplatin (sequentially timed) 100 mg/m² after 24 h prehydration on day 1 as bolus and followed by 10% mannitol diuresis
Teniposide 150 mg/m²
(sequentially timed)

Pheochromocytoma CVD regimen:⁴

Cyclophosphamide 750 mg/m² i.v. on day 1
Vincristine 1.4 mg/m² i.v. on day 1
Dacarbazine 1.4 mg/m² i.v. on days 1 and 2

NOTE: 21-day cycle with either 1-week treatment delay, or appropriate dosage modifications for hematologic or neurologic toxicities. In the absence of significant hematologic toxicity, the dosage of cyclophosphamide and dacarbazine was increased by 10% each cycle until myelo-suppression was seen. All patients received their first treatment while hospitalized.

CARCINOMA OF THE BREAST

The following are standard and effective combination chemotherapy regimen, commonly used to treat breast cancer. Over 50% response rates in previously untreated patients are reported for CAF and CMF with/without additional drug components.

NOTE: Age < 50 years or > 50 years, pre- or postmenopausal status, and negative or positive axillary nodules must be part of each chemotherapy regimen design, in addition to the condition, the hematologic-, hepatic- and renal profile of the patient.

NOTE: Limited data⁶² suggest that adjuvant therapy (FAC, CMF) should be considered in male patients with primary breast cancer.

Cyclophosphamide 500 mg/m² i.v. on day 1
Adriamycin (doxorubicin) 50 mg/m² i.v. on day 1
5-Fluorouracil 500 mg/m² i.v. on day 1

NOTE: Regimen is given every 21 days

High-dose CAF

C 600 mg/m² i.v. on day 1

A 60 mg/m² i.v. on day 1

F 600 mg/m² i.v. on day 1

NOTE: Courses are repeated every 28 days for 4 courses. High-dose CAF produces neutropenia, one must anticipate.

Oophorectomy(O) plus CAF, metastatic breast cancer in premenopausal women²⁶

O + CAF (1st cycle of CAF within 28 days of O)

C 100 mg/m² p.o. on days 1 to 14

A 30 mg/m² i.v. on days 1 and 8

F 500 mg/m² i.v. on days 1 and 8

NOTE: Each cycle restarted 29 days after the previous cycle (28 days). Cycles continued until 500 mg/m² doxorubicin(A) were administered.

Maintenance therapy for patients who had reached the maximum of 500 mg/m²:

C 100 mg/m² p.o. on days 1 to 14

Methotrexate 40 mg/m² i.v. on days 1 and 8

F 600 mg/m² i.v. on days 1 and 8

Fluoxymesterone (substituting for long-term use of prednisone, due to ADRs) 10 mg b.i.d. p.o. on days 1 to 28

FAC⁴⁰

5-Fluorouracil 500 mg/m² i.v. on days 1 **and 8**

Adriamycin(doxorubicin) 50 mg/m² i.v. on day 1

Cyclophosphamide 500 mg/m² i.v. on day 1

NOTE: Repeat cycle every 21 days

CMF Adjuvant¹¹

< 60 years

Cyclophosphamide 100 mg/m² **p.o.** on days 1 to 14
Methotrexate 40 mg/m² i.v. on days 1 and 8
5-Fluorouracil 600 mg/m² i.v. on days 1 and 8

> 60 years

Cyclophosphamide 100 mg/m² **p.o.** on days 1 to 14
Methotrexate 30 mg/m² i.v. on days 1 and 8
5-Fluorouracil 400 mg/m² i.v. on days 1 and 8

NOTE: Repeat cycle every 28 days. This regimen can also be presented as follows.^{22,50}

C 100 mg/m² **p.o.** days 1-14
M (40-60) mg/m² i.v. days 1 and 8
F (400-700) mg/m² i.v. days 1 and 8
(P) (40 mg/m²) (**p.o.**) (days 1 to 14)

C 100 mg/m² **p.o.** on days 1 to 14
M 40 mg/m² i.v. on days 1 and 8
F 600 mg/m² i.v. on days 1 and 8

NOTE: This is referred to as "standard CMF" (Milan Group)

Doxorubicin followed by CMF^{12,19,83}

(4 courses **doxorubicin** followed by 8 courses of **CMF** vs 2 courses **CMF** alternated with 1 course of doxorubicin for a total of 12 courses)

Doxorubicin 75 mg/m² i.v. bolus every 21 days for 4 courses

Beginning with course 5

Cyclophosphamide 600 mg/m² i.v. day 1 and every 21 days for 8 courses
Methotrexate 40 mg/m² i.v. day 1 and every 21 days for 8 courses
5-Fluorouracil 600 mg/m² i.v. day 1 and every 21 days for 8 courses

NOTE: This regimen is suggested as adjuvant therapy for patients with resectable breast cancer with 4 or more positive axillary nodes. If the patient becomes too neutropenic or thrombocytopenic, a 1- or 2-week therapy postponement should be initiated.

CA or AC^{22,71}

Cyclophosphamide 200 mg/m² **p.o.** days 3-6
Doxorubicin (Adriamycin) 40 mg/m² i.v. on day 1

NOTE: Recycle every 3 to 4 weeks. Total doses of **A** should not exceed 450 mg/m²

Doxorubicin (Adriamycin) 45 mg/m² i.v. on day 1
Cyclophosphamide 500 mg/m² i.v. on day 1

NOTE: Recycle every 3 weeks. Toxicity is reported high. Total doses of **A** should not exceed 450 mg/m²

RETINOBLASTOMA (Stage II to IV)²²

Chemoreduction is often employed to reduce the tumour volume to an extent that allows for focal treatment (cryotherapy, thermotherapy, plaque radiotherapy) of tumour residues. Other clinical settings where chemotherapy is considered are a high risk for or presence of metastatic disease and extraocular extensions of the tumour. Combinations of cyclophosphamide and dactinomycin, and cyclophosphamide and doxorubicin have been associated with mixed or partial responses in patients with locally extensive, regional, or distant disease. Preirradiation chemotherapy has been used for children with extensive intraocular tumours. Primary concerns are preservation of patient's vision, inhibiting tumour progression along the optic nerve, and genetic counselling of patient and patient's family.

MALIGNANT NEOPLASMS OF THE LUNG^{22, 28}

Frequently responsive:

Small-cell lung cancer (SCLC)

Effective commonly used polychemotherapy:

CAV

Cyclophosphamide	1 g to 1.5 g/m ² i.v. on day 1
Adriamycin (Doxorubicin)	45 to 70 mg/m ² i.v. on day 1 (max. total dose 450 mg)
Vincristine	1-2 mg/m ² (max. dose 2.0 mg) i.v. on day 1

NOTE: Repeat cycle every 3 weeks for up to 6 cycles

CAV alternating with EP

1 cycle of **CAV** at the lower of above doses with 1 cycle of **EP** every 3 weeks

Etoposide	100 mg/m ² i.v. days 1-3
Platinum (Cisplatin)	25 mg/m ² i.v. days 1-3

CAVE

Cyclophosphamide	1 g/m ² i.v. on day 1
Adriamycin (Doxorubicin)	50 mg/m ² i.v. on day 1
Vincristine	1.5 mg/m ² i.v. on day 1
Etoposide	60 mg/m ² i.v. days 1-5

NOTE: Repeat cycle every 3 weeks

CAE

Cyclophosphamide	1 g/m ² i.v. on day 1
Adriamycin (Doxorubicin)	45 mg/m ² i.v. on day 1
Etoposide	50 mg/m ² i.v. days 1-5

NOTE: Repeat cycle every 3 weeks

Reconstitution:

Oral Solutions: An oral elixir may be prepared by dissolving the PROCYTOX dry powder contents of the vials in "Aromatic Elixir USP" shortly before administration. The liquid oral elixir, if refrigerated at 4°C, should be used within 14 days. See STORAGE AND STABILITY, Stability of Solutions

Parenteral Products:

Solutions of PROCYTOX for parenteral use should be prepared by adding isotonic, sterile, Sodium Chloride Injection USP to the vial, and shaking the contents until dissolution and a clear solution is obtained.

Vial Size	Volume of Diluent to be Added to Vial	Approximate Available Volume	Nominal Concentration per mL
20 mL	10 mL	10 mL	20 mg/mL
50 mL	25 mL	25 mL	20 mg/mL
75 mL	50 mL	50 mL	20 mg/mL
100 mL	100 mL	100 mL	20 mg/mL

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. After reconstitution, this parenteral dosage form represents a colourless and clear solution.

Solutions showing haziness, particulate matter, precipitate, discoloration or leakage should not be used. Discard unused portion.

PROCYTOX should not be reconstituted with benzyl alcohol-preserved diluent solution such as bacteriostatic sodium chloride when used in children or infants, due to toxicity concerns in this age group (i.e., gasping syndrome in infants). Further, PROCYTOX should not be reconstituted or diluted with benzyl alcohol-containing diluents, as benzyl alcohol may catalyse the decomposition of cyclophosphamide. Therefore, it is recommended to reconstitute PROCYTOX with isotonic, sterile, Sodium Chloride Injection USP.

Heating should not be used to facilitate Dissolution

Intravenous administration preferably should be conducted as an infusion. To reduce the likelihood of adverse reactions that appear to be administration rate-dependent (e.g., facial swelling, headache, nasal congestion, scalp burning), cyclophosphamide should be injected or infused very slowly. Duration of the infusion also should be appropriate for the volume and type of carrier fluid to be infused.

If injected directly, cyclophosphamide for parenteral administration should be reconstituted with physiological saline (0.9% sodium chloride). Cyclophosphamide, reconstituted in water, is hypotonic and should not be injected directly.

For infusion, cyclophosphamide should be reconstituted by adding sterile water and infused in the recommended intravenous solutions.

Before parenteral administration, the substance must be completely dissolved.

The following solutions have been recommended as diluents for intravenous infusion:

5% dextrose USP in 0.9% sodium chloride USP

5% dextrose USP in sterile water for injection USP
0.9% sodium chloride USP

Solutions prepared with isotonic, sterile, Sodium Chloride Injection USP should only be used for a single dose administration, and any unused portion should be discarded.

Since it has been reported that immersion of a needle with an aluminum component into cyclophosphamide resulted in a slight darkening of the aluminum and gas production after a few days at 24°C with protection from light, it is recommended to avoid the use of utensils, needles or parts of infusion pumps made of aluminum in the presence of PROCYTOX.

See STORAGE AND STABILITY, Stability of Solutions
See SPECIAL HANDLING INSTRUCTIONS

OVERDOSAGE

Limited information on acute overdosage of cyclophosphamide is available.

Serious consequences of overdosage include manifestations of dose dependent toxicities such as myelosuppression, urotoxicity, cardiotoxicity (including cardiac failure), veno-occlusive hepatic disease, and stomatitis.

Patients who received an overdose should be closely monitored for the development of toxicities, and hematotoxicity in particular.

No specific antidote for cyclophosphamide is known.

Cyclophosphamide and its metabolites are dialyzable. Therefore, rapid hemodialysis is indicated when treating any suicidal or accidental overdose or intoxication.

Overdosage should be managed with supportive measures, including appropriate, state-of-the-art treatment for any concurrent infection, myelosuppression, or other toxicity, should it occur. Cystitis prophylaxis with mesna may be helpful in preventing or limiting urotoxic effects with cyclophosphamide overdose.

Cardiotoxicity may also occur with overdosage. In patients who received 4 to 10-day courses of cyclophosphamide with total dosage per course exceeding 140 mg/Kg or 5.2 g/m², cardiac damage manifested by heart failure occurred within 15 days of the initial dose. Impairment of water excretion with hyponatremia, weight gain, and inappropriately concentrated urine has been reported after cyclophosphamide doses exceeding 50 mg/Kg (2 g/m²).

At least one fatal case of cyclophosphamide overdosage had been reported; potentially fatal cardiotoxicity was the most serious consequence of overdosage. The risk of overdose with high-dose cyclophosphamide concomitantly with radiation therapy or other potentially cardiotoxic drugs (e.g: anthracyclines) must carefully be taken into consideration.

If a cyclophosphamide solution is inadvertently administered by paravenous injection, there is usually no danger of cytostatic tissue damage since such damage is not expected before cyclophosphamide has been bioactivated in the liver. Nevertheless, if paravasation should occur, stop the infusion immediately and aspirate the paravasate with the cannula in place, irrigate the area with saline solution and immobilize the extremity.

For management of a suspected drug overdose, contact your regional Poison Control Centre.

ACTION AND CLINICAL PHARMACOLOGY

Mechanism of Action

Cyclophosphamide, a nitrogen mustard derivative, is a polyfunctional alkylating agent. The parent drug is inactive *in vitro*, when tested on cultures of human leukocytes or carcinomatous cells of human origin. The active metabolite of cyclophosphamide, phosphoramidate mustard, exhibits the alkylating action. Phosphoramidate mustard is formed, following the biological transformation through oxidation by hepatic microsomal enzymes under spontaneous β -elimination of acrolein from aldophosphamide. The cytotoxic action of the active metabolite is primarily due to crosslinking of DNA and RNA strands, as well as inhibition of DNA synthesis. Cyclophosphamide is a potent immunosuppressive agent that also causes marked and persistent inhibition of cholinesterase activity. Alkylating metabolites of cyclophosphamide have been measured in cerebrospinal fluid, but, only a small fraction crosses the brain barrier.

Pharmacokinetics

Urinary Excretion of CP* (μg) after Topical Application (20 mg/mL)					
Chemotherapy: volunteers in remission	Time after drug application (hours)				
	0-6	6-12	12-18	18-24	TOTAL
A ♂	0	0	0	0	0
B ♀	0.83	2.16	2.16	6.30	11.90
C ♀	0	0	0.50	0.94	1.44
D ♀	0	2.41	5.50	----	7.9
E ♀	0	0.97	11.19	4.31	16.47

*CP=cyclophosphamide

Absorption: Cyclophosphamide is well absorbed from the gastrointestinal tract and from parenteral sites. Topical cyclophosphamide, applied to external (body surface) neoplastic tissues, appears to be absorbed. The following demonstrates that **cyclophosphamide can be absorbed through intact human skin**; therefore, requiring the protective use of unpowdered latex gloves (See SPECIAL HANDLING INSTRUCTIONS).

Bioavailability: The systemic availability, estimated from the ratio of areas under serum-concentration-time curves following oral and intravenous cyclophosphamide (CP), was reported as 97% for a 100 mg, and 74% for a 300 mg dose.

Oral CP is approximately 75% absorbed from the gastrointestinal tract. Oral administration demonstrated 3.5 times more alkylating activity than following an intravenous dose.

In all the pharmacokinetic measurements in man, large inter-individual variations must be considered

Distribution: A mean apparent volume of distribution of cyclophosphamide was 0.56 L/Kg in adults and 0.67 L/Kg in children.

Tissue Distribution of CP after i.v. administration to cancer patients indicated that both unchanged parent drug and metabolites in small quantities penetrate the blood brain barrier; brain tissue concentrations being similar to those in blood. Biopsies, performed 2 hours after CP infusion, indicated approximately 30% more radioactivity in lymph nodes compared to muscle, adipose tissue or skin, but relative proportions of unchanged drug metabolites were not established.

Protein Binding: 12 to 14% of unchanged cyclophosphamide is protein-bound; the alkylating metabolites, however, are more extensively bound, namely 67% of the total plasma alkylating activity, and in another study, 39% of phosphamide mustard was protein-bound.

Metabolism: While chemically not reactive, the primary metabolites 4-hydroxycyclophosphamide and aldophosphamide are cytotoxic *in vitro*, and may represent transport forms of the alkylating moiety, phosphoramidate mustard. The two primary metabolites can be further oxidized into the major urinary metabolites 5-ketocyclophosphamide and carboxyphosphamide. Nor-nitrogen mustard, a decomposition product of carboxyphosphamide, is an active alkylating agent with cytotoxicity *in vivo* and *in vitro*, however, little antitumour activity could be demonstrated; yet, it may play a role in the hematopoietic and other toxicities of cyclophosphamide. Another metabolite formed from aldophosphamide is acrolein, which has been identified as the most urotoxic species.

Disposition Kinetics: The decline in CP plasma levels following an i.v. dose is biexponential with terminal half-life averaging 7 hours (1.8 to 12.4) for adults, and 4 hours (2.4 to 6.5) for children; daily administration of approximately 50 mg/Kg bid or qid (i.v. infusion) to children significantly decreased both plasma half life and urinary excretion of CP. With daily exposure or repeated high-dose administration (i.v.) of cyclophosphamide to adult patients, the half-life of CP decreased without an increase in urinary excretion, suggesting that the drug induces its own metabolism. After an i.v. dose, the NBP [4-(nitrobenzyl)-pyridine] plasma alkylating activity peaks 2 hours after administration, and declines with a half-life of 7.7 hours. Phosphoramidate mustard in 3 patients, receiving 60-75 mg/Kg cyclophosphamide, peaked 2 to 3 hours after the administration of CP at levels 10 to 20% of the unchanged drug, and declined slowly with levels still detectable at 24 hours.

Even with doses as high as 80 mg/Kg, the plasma half-life of CP does not increase.

The $t_{1/2}$ and AUC of cyclophosphamide after a 5-day continuous infusion schedule of 300-400

mg/m²/day, were similar to the t_{1/2} and AUC of a 1500 mg/m² i.v. bolus. The AUC of the alkylating activity after 5-day i.v. infusion, however, was three times higher than the AUC of alkylating activity after 1500 mg/m² i.v. bolus administration of cyclophosphamide. After CP administration to man and laboratory animals, significant differences in the pharmacokinetic parameters of the active metabolite 4-hydroxycyclophosphamide in both man and animals were found. In man, the active metabolite in blood was found at only low but longer lasting concentrations compared to the high and relatively short time concentration in blood of mice and rats, after a comparable dose.

Excretion: In man, a generally higher proportion of the administered CP is excreted as metabolites in urine. Urinary recovery of radioactivity after intravenously administered ¹⁴C-cyclophosphamide to patients ranged from 59 to 82% after 4 days, while not more than 20% of i.v. cyclophosphamide was excreted unchanged in urine at any dose level.

Renal clearance estimates of between 5.3 and 11 mL/min indicate substantial renal tubular reabsorption.

Special Populations and Conditions

Hepatic Insufficiency: A patient with Hodgkin's disease showing jaundice, markedly elevated alkaline phosphatase and filling defects on liver scan had the longest cyclophosphamide half life (8.4 hrs) and lowest peak plasma alkylating metabolite level (4.2 μmoles/mL) of 12 patients having received 40 mg/Kg CP. Prior hepatic dysfunction and/or hepatotoxic medication might predispose the patient to oral cyclophosphamide toxicity by altering the balance between the enzymatic production of non-toxic metabolites (carboxyphosphamide) and the decomposition of aldophosphamide to the effective alkylating agent phosphoramidate mustard.

Renal Insufficiency: Patients with severe renal function impairment have a normal biotransformation of cyclophosphamide, but impaired excretion of metabolites with significantly higher plasma alkylating activity. Dose modification of cyclophosphamide, related to the degree of renal dysfunction, may be advised. Patients with moderate to severe renal impairment receiving high doses of cyclophosphamide or those with severe renal impairment receiving conventional doses may require dose reduction, e.g., a dose reduction of 50% for a glomerular filtration rate below 10 mL/minute is recommended.

Cyclophosphamide is dialysable with a high extraction efficiency.

STORAGE AND STABILITY

The recommended storage temperature for the PROCYTOX dosage forms is 15-25 °C. The dosage forms should be protected from direct light.

During transport or storage of PROCYTOX injection vials, temperature fluctuations can lead to melting of the active ingredient, cyclophosphamide. Vials containing melted substance are easily noticeable, since the powder becomes a clear or viscous yellow liquid (seen as droplets or

a connected phase in the affected vials). Do not use vials with melted content.

Stability of Solutions

Storage:

Reconstituted solutions are chemically stable for 24 hours at 15-25 °C, or 72 hours under refrigeration (4°C). Unless prepared under aseptic conditions, reconstituted solutions should be used within 8 hours after dilution.

The liquid oral elixir, if refrigerated at 4°C, should be used within 14 days.

SPECIAL HANDLING INSTRUCTIONS

Handling and Disposal

Cyclophosphamide (PROCYTOX) is cytotoxic, carcinogenic, mutagenic and teratogenic. Avoid ingestion, inhalation, or skin and eye contact. Mandatory washing of hands before and after using gloves must be advised. If necessary, consult the Company's **Material Safety Data Sheet**.

Personnel, regularly handling these agents should have frequent hematologic examinations (CBC), and frequently be screened for urine mutagenesis.

Work-practice guidelines for personnel dealing with and handling cytotoxic and hazardous preparations must be respected, to minimize unnecessary exposure to cyclophosphamide in physicians, nurses, pharmacists, and technicians.

Appropriate Personal Protective Equipment (PPE) must be available in all areas where cyclophosphamide is handled. See the following table:

Activity (When to Wear)	Personal Protective Equipment (PPE)			
	Gloves:	Gown:	Eye Protection:	Mask:
	Surgical Latex (7-9 mil thickness) or material which provides equal or better protection. Gloves must be changed at least hourly or immediately if contaminated, torn or punctured. Wash hands with soap and water after removal of gloves	Moisture-resistant, long-sleeved gown with cuffs. Gowns must be changed daily, immediately if contaminated and immediately after spill clean-up.	Eye/face protection (e.g., chemical splash goggles) must be worn when there is hazard of eye contact.	(As approved by Workers Compensation Board)
Preparation	Always	Always	If preparing outside a biological safety cabinet	No
Administration	Always	Always	If hazard of eye contact	No
Spill Clean-up	Always	Always	Always	Yes

Waste Disposal	Always	If waste uncontained	If waste uncontained	No
-----------------------	--------	----------------------	----------------------	----

Preparation of PROCYTOX must take place in a Pharmacy or, in facilities where there is not a Pharmacy, in a Class II Type B or better, externally-vented biological safety cabinet. The biological safety cabinet should have airflow monitoring devices and should be certified at least annually. Only luer-lock connections should be used in the preparation of PROCYTOX.

Disposal of **cyclophosphamide**-contaminated clothing, gloves, utensils, broken glass etc. must be considered as hazardous waste. It must be deposited into a 4 mil thick polypropylene hospital trash bag (properly labelled), or be otherwise segregated and incinerated at above 1000°C. Chemical inactivation should, if possible, be avoided, since it is often ineffective and may produce byproducts that are more mutagenic than the parent drug.

Spills: Cleaning up immediately and decontaminating areas of spills and breakage by experienced and well-protected personnel is of utmost importance. Contaminated areas including hood interiors must have clearly worded warning labels posted. It is suggested that spill kits be easily accessible, and include replacement hood filters, a respirator (“P3” filter, Manufacturer’s current recommendation for cyclophosphamide powder spills), chemical splash goggles, at least 2 pairs of protective gloves, at least 2 sheets (31 cm x 33cm/12" x 13") of absorbent material, 250 mL and 1 Liter spill-control pillows, a small scoop, spatula, forceps or tweezers to collect glass fragments, and at least two large polypropylene hospital trash bags 4 mil or thicker, or other cytotoxic drug waste-disposal bags, puncture- and leak-resistant waste container for sharp or breakable objects or spilled liquid, and warning sign (e.g., “ Danger - Cytotoxic Agent Spill”). Absorbents should be incinerable.

DOSAGE FORMS, COMPOSITION AND PACKAGING

PROCYTOX (Cyclophosphamide Tablets, USP):

<i>Label Strength</i>	<i>Active Ingredient (cyclophosphamide, USP)</i>	<i>Description</i>	<i>Availability</i>
25 mg	26.7 mg cyclophosphamide monohydrate equivalent to 25 mg anhydrous cyclophosphamide	Round, deeply biconvex, white to off-white, sugar-coated	Bottles of 200 tablets
50 mg	53.5 mg cyclophosphamide monohydrate equivalent to 50 mg anhydrous cyclophosphamide	Round, deeply biconvex, off-white, sugar-coated	Bottles of 500 tablets Blisters of 10 tablets, in boxes containing 50 or 100 tablets

COMPOSITION

The PROCYTOX (cyclophosphamide) 25 mg and 50 mg tablets have the same formulation, containing the following Non-Medicinal Ingredients (in alphabetic order): Calcium carbonate, Dibasic Calcium phosphate, Cellulose, Gelatin, Glycerin, Lactose, Magnesium stearate, Polyethylene glycol, Polysorbate, Povidone, Silicon dioxide, Starch (Corn), Sucrose, Talc, Titanium dioxide, Wax.

PROCYTOX (Cyclophosphamide for Injection):

Vials containing cyclophosphamide for reconstitution.

200 mg, 500 mg, 1000 mg, 2000 mg

Single vials, and boxes of 10

COMPOSITION

PROCYTOX vials contain only the labelled amount of cyclophosphamide. There are no excipients.

See STORAGE AND STABILITY

PART II: SCIENTIFIC INFORMATION

PHARMACEUTICAL INFORMATION

Drug Substance


Proper name: Cyclophosphamide BP & USP

Chemical name: 2-[Bis(2-chloroethyl)]amino tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate

Other Names: B 518, NSC 26271, CYP, ENDOXAN-ASTA

Molecular formula and molecular mass: $C_7H_{15}Cl_2N_2O_2P \cdot H_2O$ and 279.10

Structural formula:



Physicochemical properties:

Physical Form: White, almost odourless crystalline powder

Solubility: Soluble in water, slightly soluble in alcohol, sparingly soluble in ether

pH Values: **4.0 - 6.0** (2% solution in water) **BP**
3.9 - 7.1 (1% solution in water) **USP**

Melting Point: **49.5C - 53C** **BP** with gel-like decomposition at 53.5C **BP**

DETAILED PHARMACOLOGY

Preclinical Pharmacology

The reported difference in intravenous and oral AUC values between man and mice is in line with several reports of appreciable species differences in cyclophosphamide (**CYP**) metabolism, thought to be primarily due to variations in hepatic microsomal metabolism.

AUC data for cyclophosphamide (CYP) and major metabolites in man (mg x h/mL), and in mice (mg x min/mL)

METABOLITE	I.V. 1 g vs 200 mg/Kg		P.O. 1 g vs 200 mg/Kg		RATIO I.V. vs P.O.	
	MAN	MICE	MAN	MICE	MAN	MICE
Cyclophosphamide	21.9	322	19.5	55	0.89	0.17
4-hydroxy-CYP	1.2	24	1.0	18	0.83	0.75
4-keto-CYP	1.3	187	1.3	97	1.00	0.52
Carboxyphosphamide	12.0	247	10.5	48	0.88	0.19
Phosphoramidate mustard	1.2	18	0.9	13	0.75	0.72

In the rat, following a 200 mg/Kg i.p. cyclophosphamide injection, a plasma elimination $t_{1/2}$ of 1.1 hours was reported, comparing to a mouse plasma elimination $t_{1/2}$ of only 0.2 hours. In the rat, the tissue cyclophosphamide elimination $t_{1/2}$ was largest in liver, lung and kidney. The highest tissue concentration was found in the kidneys.

Cyclophosphamide is an effective agent against the B-16 melanoma in C57BL/6 mice. The effect is dose-related over a range of from 50 to 200 mg/Kg; the latter dose of 200 mg/Kg causes a 120% increase in the median survival time. 10 mg/Kg is required to kill 50% of the tumor cells in vivo with a tumor strain that has a doubling time of 1 day.

Cyclophosphamide in animals inhibits immune phenomena, inflammatory processes, delayed hypersensitivity reactions, experimental allergic inflammatory disease, and defenses against infectious micro-organisms.

TOXICOLOGY

Acute Toxicity

The following lethality studies were undertaken in male and female CDF₁ mice, using single or multiple i.v. cyclophosphamide dose regimen.

SINGLE DOSE	MALE	FEMALE
LD ₉₀	828.01 mg/Kg	652.92 mg/Kg
LD ₅₀	524.46 mg/Kg	416.99 mg/Kg
LD ₁₀	332.19 mg/Kg	265.10 mg/Kg
SINGLE DOSE x 5	MALE	FEMALE
LD ₉₀	191.69 mg/Kg	131.30 mg/Kg
LD ₅₀	145.49 mg/Kg	79.37 mg/Kg
LD ₁₀	110.43 mg/Kg	47.98 mg/Kg

Intravenous LD₅₀ was reported as 40 mg/Kg for dogs, 130 mg/Kg for rabbits, 160 mg/Kg for rats, and 400 mg/Kg for guinea pigs.

Oral LD ₅₀ for cyclophosphamide in mice after:		in rats after:
24 h	780 mg / Kg	---
48 h	750 mg / Kg	720 mg / Kg
120 h	600-726 mg / Kg	235 mg / Kg
7 days	580 mg / Kg	142 mg / Kg
14 days	350 mg / Kg	94 mg / Kg

The 14-day LD₅₀ for oral cyclophosphamide in dogs was reported as 44 mg/Kg.

Subcutaneous 100 mg/Kg chloramphenicol prior to 300 mg/Kg or 200 mg/Kg i.p. cyclophosphamide in adult rats is capable of partially protecting against the toxic and lethal effects of cyclophosphamide.

The efficacy of 50 mg/Kg i.p. cyclophosphamide in 150 to 200 newborn and adult Swiss male mice per experiment under depleted and supplemented condition of vitamin A (p.o. 100 and 250 IU/mouse/day) was scrutinized. Supplemental vitamin A helped to check progression of solid murine sarcoma 180 growth, and also increased the effectiveness of chemotherapy.

Cyclophosphamide titration in mice appears to enhance survival following treatment with cyclophosphamide up to, but not exceeding 450 mg/Kg. Hematuria was very much lower in the titrated group, also lung damage was less in the titrated mice.

Intraperitoneal injection of cyclophosphamide, acrolein and phosphamide mustard into mice was used, to determine, which of the metabolites is responsible for ovarian toxicity. Using follicle destruction, ovarian volume and uterine weight as toxicity parameters, the investigators found only phosphoramidate mustard responsible for cyclophosphamide ovarian toxicity.

Chronic Toxicity

Studies, using rats that received up to 12 mg/Kg cyclophosphamide by stomach tube for 80 days, indicated that the highest dose produced a 75% mortality rate after 8 weeks. Leukopenia was observed in all animals after 4 weeks of treatment. A high incidence of hematuria and petechial hemorrhage was found in lungs, gastrointestinal tract and urinary bladder.

Dogs receiving cyclophosphamide p.o. of up to 5 mg/Kg 5 days a week for 6 weeks, presented a reduction in body weight, leukopenia and limited hemorrhagic lesions in lymph nodes, bladder, brain, lung, gastrointestinal tract and renal pelvis. Severity of bone marrow changes was related to dosage.

Chronic administration of toxic doses led to hepatic lesions manifested as fatty degeneration followed by necrosis. The intestinal mucosa was not affected. The threshold for hepatotoxic effects was 100 mg/Kg in the rabbit and 10 mg/Kg in the dog.

The carcinogenic effect of cyclophosphamide was demonstrated not only in rats but also in mice. Cyclophosphamide is mutagenic in animals.

Reproductive and teratologic toxicity of cyclophosphamide in animals is well documented.

REFERENCES

1. Ahmed AR, Hombal ShM. Cyclophosphamide - A review on relevant pharmacology and clinical uses. *J Am Acad Dermatol* 1984, 11(6): 1115-1126
2. Amadori S, Guglielmi C, Anselmo AP, Cimino G, Ruco LP, Papa G, Biagini C, Mandelli F. Treatment of diffuse aggressive non-Hodgkin's lymphomas with an intensive multi-drug regimen including high-dose cytosine arabinoside (F-MACHOP). *Semin Oncol* 1985, 12(Suppl.3): 218-222
3. Amadori D, Nanni O, Marangolo M, Pacini P, Ravaioli A, Rossi A, Catalano G, Perroni D, Scarpi E, Giunchi D, Tienghi A, Bacciolini A, Volpi A. Disease free survival advantage of adjuvant cyclophosphamide, methotrexate, and fluorouracil in patients with node-negative, rapidly proliferating breast cancer: A randomized multicenter study. *J Clin Oncol* 2000, 18(17):3125-3134
4. Averbuch StD, Steakley CS, Young RC, Gelmann EP, Goldstein DS, Stull R, Keiser HR. Malignant pheochromocytoma: Effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine. *Ann Intern Med* 1988, 109: 267-273
5. Ayash LJ, Wright JE, Tretyakov O, Gonin R, Elias A, Frei E III. Cyclophosphamide pharmacokinetics: correlation with cardiac toxicity and tumor response. *J Clin Oncol* 1992, 10: 995-1000
6. Bacon AM, Rosenberg StA. Cyclophosphamide hepatotoxicity in a patient with systemic lupus erythematosus. *Ann Intern Med* 1982, 97(1): 62-63
7. Bagley ChM Jr, Bostick FW, de Vita VT Jr. Clinical pharmacology of cyclophosphamide. *Cancer Res* 1973, 33: 226-233
8. Beijnen JH, van Gijn R, Challa EE, Kaijser GP, Underberg WJM. Chemical stability of two sterile, parenteral formulations of cyclophosphamide (Endoxan[®]) after reconstitution and dilution in commonly used infusion fluids. *J Parent Sci Technol* 1982, 46(4): 111-116
9. Bending MR, Finch RE. Haemodialysis during cyclophosphamide treatment. *B M J* 1978, (29.04): 1145-1146
10. Bierman PJ, Anderson JR, Freeman MB, Vose JM, Kessinger A, Bishop MR, Armitage JO. High-dose chemotherapy followed by autologous hematopoietic rescue for Hodgkin's disease patients following first relapse after chemotherapy. *Ann Oncol* 1996, 7: 151-156
11. Bonadonna G, Brusamolino E, Valagussa P, Rossi A, Brugnatelli L, Brambilla C, DeLena M, Tancini G, Bajetta E, Musumeci R, Veronesi U. Combination chemotherapy as an adjuvant treatment in operable breast cancer. *N E J M* 1976, 294(8): 405-410
12. Bonadonna G, Zambetti M, Valagussa P. Sequential or alternating doxorubicin and CMF

- regimens in breast cancer with more than three positive nodes. Ten-year results. *J A M A* 1995, 273(7): 542-547
13. Bonadonna G, Valagussa P, Brambilla C, Ferrari L, Moliterni A, Terenziani M, Zambetti M. Primary chemotherapy in operable breast cancer: Eight-year experience at the Milan Cancer Institute. *J Clin Oncol* 1998, 16(1):93-100
 14. Brock N. Comparative pharmacologic study in vitro and in vivo with cyclophosphamide (NSC-26271), cyclophosphamide metabolites, and plain nitrogen mustard compounds. *Cancer Treat Rep* 1976, 60(4): 301-308
 15. Brooke D, Bequette RJ, Davis RE. Chemical stability of cyclophosphamide in parenteral solutions. *Am J Hosp Pharm* 1973, 30: 134-137
 16. Brooke D, Davis RE, Bequette RJ. Chemical stability of cyclophosphamide in aromatic elixir USP. *Am J Hosp Pharm* 1973, 30(07): 618-620
 17. Brooke D, Scott JA, Bequette RJ. Effect of briefly heating cyclophosphamide solutions. *Am J Hosp Pharm* 1975, 32: 44-45
 18. Brufman G, Colajori E, Ghilezan N, Lassus M, Martoni A, Perevodchikova N, Toseelo C, Viaro D, Zielinsk C, Epirubicin High Dose (HEPI 010) Study Group. Doubling epirubicin dose intensity (100 mg/m² versus 50 mg/m²) in the FEC regimen significantly increases response rates. An international randomised phase III study in metastatic breast cancer. *Ann Oncol* 1997 8:155-162
 19. Buzzoni R, Bonadonna G, Valagussa P, Zambetti M. Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes. *J Clin Oncol* 1991, 9: 2134-2140
 20. Colvin M, Hilton J. Pharmacology of cyclophosphamide and metabolites. *Cancer Treat Rep* 1981, 65(Suppl.3): 89-95
 21. Coombes RC, Bliss JM, Morvan JWF, Espié M, Amadori D, Gambrosier P, Richards M, Aapro M, Villar-Grimalt A, McArdle C, Pérez-Lopez FR, Vassilopoulos P, Ferreira EP, Childers CED, Coombes G, Woods EM, Marty M. Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. *J Clin Oncol* 1996, 14: 34-45
 22. De Vita VT Jr, Hellman S, Rosenberg StA (Eds). *Cancer. Principles and practice of oncology*. 4th ed. Vol.2 of 2, pp.1333-2747 J.B. Lippincott, Philadelphia 1993 (ISBN 0-397-51321-6)
 23. Dimopoulos MA, Weber D, Kantarjian H, Delasalle KB, Alexanian R. HyperCVAD for

VAD-resistant multiple myeloma. *Am J Hematol* 1996, 52: 77-81

24. Dusenbery KE, Peterson BA, Bloomfield CD. Chemotherapy with cyclophosphamide, vinblastine, procarbazine, and prednisone (CVPP) for Hodgkin Disease. Fourteen-year follow-up results. *Am J Hematol* 1988, 28: 246-251
25. EDI St.Louis, MO 1997, loose leaf, p.9/6.01/1988
26. Esteban E, Lacave AJ, Fernandez JL, Corral N, Buesa J, Estrada E, Palacio I, Vietez J, Muñiz I, Alvarez E. Phase III trial of cyclophosphamide, epirubicin, fluorouracil (CEF) versus cyclophosphamide, mitoxantrone, fluorouracil (CNF) in women with metastatic breast cancer. *Breast Cancer Res Treat* 1999, 58:141-150
27. Falkson G, Holcroft C, Gelman RS, Tormey DC, Wolter JM, Cummings FJ. Ten-year follow-up study of premenopausal women with metastatic breast cancer: an Eastern Cooperative Oncology Group Study. *J Clin Oncol* 1995, 13: 1453-1458
28. Finkstein JZ, Klemperer MR, Evans A, Bernstein I, Leikin S, McCreadie S, Grosfeld J, Hittle R, Weiner J, Sather H, Hammond D. Multiagent chemotherapy for children with metastatic neuroblastoma: A report from Childrens Cancer Study Group. *Med Pediatr Oncol* 1979, 6: 179-188
29. Fischer DS, Tish Knobf M, Durivage HJ (Eds). *The cancer chemotherapy handbook* 4th ed. Mosby, St. Louis 1993, 527p (ISBN 0-8016-6882-4)
30. Fisher RI, Gaynor ER, Dahlberg St, Oken MM, Grogan ThM, Mize EM, Glick JH, Coltman ChA, Miller ThP. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. *N E J M* 1993, 328(14): 1002-1006
31. Fisher RI, Gaynor ER, Dahlberg St, Oken MM, Grogan ThM, Mize EM, Glick JH, Coltman ChA, Miller ThP. A phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOB-B in patients with intermediate- or high-grade non-Hodgkin's lymphoma: results of SWOG-8516 (Intergroup 0067), the national high-priority lymphoma study. *Ann Oncol* 1994, 5(Suppl.2): S91-S95
32. Ford CD, Warnick CT. DNA damage and repair in patients receiving high-dose cyclophosphamide and radiation. *NCI Monogr* 1988, No.6: 41-44
33. Garas G, Crawford GP, Cain M. Anaphylactic reaction to intravenous cyclophosphamide. *Aust NZ J Med* 1995, 25: 59
34. Garrick CL, Cronin SM, Sensenbrenner LL. Effect of mesna on cyclophosphamide. *DICP. Ann Pharmacother* 1989, 23: 798-799
35. Gilchrist DM, Friedman JM, (Kirshon B, reply). Teratogenesis and i.v. cyclophosphamide. *J*

Rheumatol 1989, 16(7): 1008-1009

36. Goldschmidt H, Hegenbart U, Haas R, Hunstein W. Mobilization of peripheral blood progenitor cells with high-dose cyclophosphamide (4 or 7 g/m²) and granulocyte colony-stimulating factor in patients with multiple myeloma. *Bone Marrow Transpl* 1996, 17: 691-697
37. Grochow LB, Colvin M. Clinical pharmacokinetics of cyclophosphamide. *Clin Pharmacokinet* 1979, 4: 380-394
38. Guglielmi C, Amadori S, Ruco LP, Mantovani L, Martelli M, Papa G, Mandelli F. Combination chemotherapy for the treatment of diffuse aggressive lymphomas: F-MACHOP update. *Semin Oncol* 1987, 14(Suppl.1): 104-109
39. Hainsworth JD, Wolff StN, Stein RS, Greer JP, Cousar JB, Greco FA. Effects of Mega-COMLA (Cyclophosphamide, cytarabine, vincristine, and methotrexate followed by leucovorin and prednisone) plus CHOP (Cyclophosphamide, doxorubicin, vincristine, and prednisone) in the treatment of lymphoid neoplasms with very poor prognosis. *Cancer Treat Rep* 1986, 70(8): 953-958
40. Haselberger MB, Schwinghammer TL. Efficacy of mesna for prevention of hemorrhagic cystitis after high-dose cyclophosphamide therapy. *Ann Pharmacother* 1995, 29(Sep): 918-921
41. Hortobagyi GN, Gutterman JU, Blumenschein GR, Tashima ChK, Burgess MA, Einhorn L, Buzdar AU, Richman StP, Hersh EM. Combination chemoimmunotherapy of metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, and BCG. *Cancer* 1979, 43(4): 1225-1233
42. Karchmer RK, Hansen VL. Possible anaphylactic reaction to intravenous cyclophosphamide. Report of a case. *J A M A* 1977, 237(5): 475
43. Kaye FJ, Bunn PA Jr, Steinberg SM, Stocker JL, Ihde DC, Fischmann AB, Glatstein EJ, Schechter GP, Phelps RM, Foss FM, Parlette HL III, Anderson MJ, Sausville EA. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. *N E J M* 1989, 321(26): 1784-1790
44. Kessinger A, Bierman PhJ, Vose JM, Armitage JO. High-dose cyclophosphamide, carmustine, and etoposide followed by autologous peripheral stem cell transplantation for patients with relapsed Hodgkin's disease. *Blood* 1991, 77(11): 2322-2325
45. Levine MN, Bramwell VH, Pritchard KI, Norris B, Shepherd L, Abu-Zahra H, Findlay B, Warr D, Bowman D, Myles J, Arnold A, Venedberg T, MacKenzie R, Robert J, Ottaway J, Burnell M, Williams C, Tu D. Randomized trial of intensive cyclophosphamide, epirubicin,

and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. *J Clin Oncol* 1998, 16:2651-2658

46. Linch DC, Winfield D, Goldstone AH, Moir D, Hancock B, McMillan A, Chopra R, Milligan D, Hudson GV. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. *Lancet* 1993, 341(24.04): 1051-1054
47. Long GD, Chao NJ, Hu WW, Negrin RS, Wong RM, Blume KG. High dose etoposide-based myeloablative therapy followed by autologous blood progenitor cell rescue in the treatment of multiple myeloma. *Cancer* 1996, 78: 2502-2509
48. Longo DL. The use of chemotherapy in the treatment of Hodgkin's disease. *Semin Oncol* 1990, 17(6): 716-735
49. Luce JK, Simons JA. Efficacy of mesna in preventing further cyclophosphamide-induced hemorrhagic cystitis. *Med Pediatr Oncol* 1988, 16: 372-374
50. MacLennan ICM, Chapman C, Dunn J, Kelly K. Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis. *Lancet* 1992, 339(25.01): 200-204
51. Marschke RF Jr, Ingle JN, Schaid DJ, Krook JE, Mailliard JA, Cullinan StA, Pfeifle DM, Votava HJ, Ebbert LP, Windschitl HE. Randomized clinical trial of CFP versus CMFP in women with metastatic breast cancer. *Cancer* 1989, 63(10): 1931-1937
52. Maulard-Durdux C, Dufour B, Hennequin Ch, Delanian S, Housset M. Phase II study of the oral cyclophosphamide and oral etoposide combination in hormone-refractory prostate carcinoma patients. *Cancer* 1996, 77(6): 1144-1148
53. Ménard S, Valagussa P, Pilotti S, Gianni L, Biganzoli E, Boracchi P, Tomasic G, Casalini P, Marubini E, Colnaghi M, Cascinelli N, Bonadonna G. Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables. *J Clin Oncol* 2001, 19(2):329-335
54. Miller LJ, Chandler SW, Ippoliti CM. Treatment of cyclophosphamide-induced hemorrhagic cystitis with prostaglandins. *Ann Pharmacother* 1994, 28: 590-594
55. Milsted RAV, Jarman M. Haemodialysis during cyclophosphamide treatment. *B M J* 1978, (1.04): 820-821
56. Mirkes PhE. Cyclophosphamide teratogenesis: A review. *Teratog Carcinog Mutagen* 1985, 5: 75-88
57. Misset J-L, di Palma M, Delgado M, Plagne R, Chollet Ph, Fumoleau P, LeMevel B,

- Belpomme D, Guerrin J, Fargeot P, Metz R, Ithzaki M, Hill K, Mathé G. Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration. *J Clin Oncol* 1996, 14: 1136-1145
58. Monconduit M, Menard JF, Michaux JL, LeLoet X, Bernard JF, Grosbois B, Pollet JP, Azais I, Laporte JPh, Doyen C, De Gramont A, Wetterwald M, Duclos B, Euller-Ziegler L, Peny AM. VAD or VMBCP in severe multiple myeloma. *Br J Haematol* 1992, 80: 199-204
59. Moore MJ. Clinical pharmacokinetics of cyclophosphamide. *Clin Pharmacokinet* 1991, 20(3): 194-208
60. Morgenfeld M, Somoza N, Magnasco J, Parlovsky S, de Bonesana AC, Bezares R, Suarez A, Pileggi J, Lein JM, Macchi A, Calabria SI, Garay GE, de Sica SC, Besuschio S. Combined chemotherapy cyclophosphamide, vinblastine, procarbazine and prednisone (CVPP) vs. CVPP plus CCNU (CCVPP) in Hodgkin's disease. *Cancer* 1979, 43(5): 1579-1586
61. Murgo AJ, Weinberger BB. Pharmacological bone marrow purging in autologous transplantation: focus on the cyclophosphamide derivatives. *Crit Rev Oncol/Hematol* 1993, 14: 41-60
62. Niitsu N, Umeda M. COP-BLAM regimen combined with granulocyte colony-stimulating factor and high-grade non-Hodgkin's lymphoma. *Eur J Haematol* 1995, 55: 88-92
63. Patel HZ (II), Buzdar AU, Hortobagyi GN. Role of adjuvant chemotherapy in male breast cancer. *Cancer* 1989, 64(8): 1583-1585
64. Piccart MJ, Bruning P, Wildiers J, Awada A, Schornagel JH, Thomas J, Tomiak E, Bartholomeus S, Witteveen PO, Paridaens R. An EORTC pilot study of filgrastim (recombinant human granulocyte colony-stimulating facto) as support to a high dose-intensive epidriamycin-cyclophosphamide regimen in chemotherapy-naive patients with locally advanced or metastatic breast cancer. *Ann Oncol* 1995, 6: 673-677
65. Plantaz D, Rubie H, Michon J, Mechinaud F, Coze C, Chastagner P, Frappaz D, Gigaud M, Passagia JG, Hartmann O. The treatment of neuroblastoma with intraspinal extension with chemotherapy followed by surgical removal of residual disease. A prospective study of 42 patients - Results of the NBL 90 Study of the French Society of Pediatric Oncology. *Cancer* 1996, 78(2): 311-319
66. Power LA. ASHP technical assistance bulletin on handling cytotoxic and hazardous drugs. *Am J Hosp Pharm* 1990, 47: 1033-1049
67. Power LA, Anderson RW, Cortopassi R, Gera JR, Lewis RM Jr. Update on safe handling of hazardous drugs: The advice of experts. *Am J Hosp Pharm* 1990, 47: 1050-1060
68. Reece DE, Barnett MJ, Connors JM, Fairey RN, Greer JP, Herzig GP, Herzig RH,

- Klingemann H-G, O'Reilly SE, Shepherd JD, Spinelli JJ, Voss NJ, Wolff StN, Phillips GL. Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease. *J Clin Oncol* 1991, 9: 1871-1879
69. Reiter A, Schrappe M, Ludwig W-D, Hiddemann W, Sauter S, Henze G, Zimmermann M, Lampert F, Havers W, Niethammer D, Odenwald E, Ritter J, Mann G, Welte K, Gadner H, Riehm H. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. *Blood* 1994, 84(9): 3122-3133
70. Riccardi A, Tinelli C, Brugnattelli S, Pugliese P, Giardina V, Giordano M, Danova M, Richetti A, Fava S, Rinaldi E, Fregoni V, Trotti G, Poli A. Doubling of the epirubicin dosage within the 5-fluorouracil, epirubicin, and cyclophosphamide regimen: a prospective, randomized, multicentric study on antitumor effect and quality of life in advanced breast cancer. *Int J Oncol* 2000, 16:769-776
71. Ringdén O, Labopin M, Tura S, Arcese W, Irondo A, Zittoun R, Sierra J, Gorin NC. A comparison of busulphan versus total body irradiation combined with cyclophosphamide as conditioning for autograft or allograft bone marrow transplantation in patients with acute leukemia. *Br J Haematol* 1996, 93: 637-645
72. Rosner D, Nemoto T, Lane WW. A randomized study of intensive versus moderate chemotherapy programs in metastatic breast cancer. *Cancer* 1987, 59(5): 874-883
73. Sauer H, Füger K, Blumenstein M. Modulation of cytotoxicity of cytostatic drugs by hemodialysis in vitro and in vivo. *Treat Rev* 1990, 17:293-300.
74. Schiller G, Vescio R, Freytes C, Spitzer G, Sahebi Firoozeh S, Lee M, Hua Wu Ch, Cao J, Lee JC, Hong ChH, Lichtenstein A, Lill M, Hall J, Berenson R, Berenson J: Transplantation of CD34⁺ peripheral blood progenitor cells after high-dose chemotherapy for patients with advanced multiple myeloma. *Blood* 1995, 86(1): 390-397
75. Seymour JF, McLaughlin P, Fuller LM, Hagemester FB, Hess M, Swan F, Romaguera J, Rodriguez MA, Besa P, Cox J, Cabanillas F. High rate of prolonged remissions following combined modality therapy for patients with localized low-grade lymphoma. *Ann Oncol* 1996, 7: 157-163
76. Shafford EA, Rogers DW, Pritchard J. Advanced neuroblastoma: improved response rate using a multiagent regimen (OPEC) including sequential cisplatin and VM-26. *J Clin Oncol* 1984, 2(7): 742-747
77. Sheridan WP, Wolf M, Lusk J, Layton JE, Souza L, Morstyn G, Dodds A, Maher D, Green MD, Fox RM. Granulocyte colony-stimulating factor and neutrophil recovery after high-dose chemotherapy and autologous bone marrow transplantation. *Lancet* 1989, II(14.10): 891-895
78. Sladek NE, Priest J, Doeden D, Mirocha CJ, Pathre S, Krivit W. Plasma half-life and urinary

excretion of cyclophosphamide in children. *Cancer Treat Rep* 1980, 64(10-11): 1061-1066

79. Taylor KM, Jagannath S, Spitzer G, Spinolo JA, Tucker SL, Fogel B, Cabanillas FF, Hagemester FB, Souza LM. Recombinant human granulocyte colony-stimulating factor hastens granulocyte recovery after high-dose chemotherapy and autologous bone marrow transplantation in Hodgkin's disease. *J Clin Oncol* 1989, 7: 1791-1799
80. Tchekmedyian NS, Egorin MJ, Cohen BE, Kaplan RS, Poplin E, Aisner J. Phase I clinical and pharmacokinetic study of cyclophosphamide administered by five-day continuous intravenous infusion. *Cancer Chemother Pharmacol* 1986, 18: 33-38
81. Tubergen DG, Krailo MD, Meadows AT, Rosenstock J, Kadin M, Morse M, King D, Steinherz PG, Kersey JH. Comparison of treatment regimens for pediatric lymphoblastic non-Hodgkin's lymphoma: children's cancer group study. *J Clin Oncol* 1995, 13: 1368-1376
82. Vadhan-Raj S, Keating M, LeMaistre A, Hittelman WN, McCredie K, Trujillo JM, Broxmeyer HE, Henney Ch, Gutterman JU. Effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. *N E J M* 1987, 317(25): 1545-1552
83. Voelcker G, Wagner Th, Wientzek C, Hohorst H-J. Pharmacokinetics of "activated" cyclophosphamide and therapeutic efficacies. *Cancer* 1984, 54(6): 1179-1186
84. Weiss RB, Valagussa P, Moliterni A, Zambetti M, Buzzoni R, Bonadonna G. Adjuvant chemotherapy after conservative surgery plus irradiation versus modified radical mastectomy. *Am J Med* 1987, 83(Sep): 455-463
85. Wheeler C, Antin JH, Churchill WH, Come StE, Smith BR, Bublely GJ, Rosenthal DS, Rappaport JM, Ault KA, Schnipper LE, Eder JP. Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study. *J Clin Oncol* 1990, 8: 648-656
86. Wiernik PH, Duncan JH. Cyclophosphamide in human milk. *Lancet* 1971, I(1.05): 912 (Letter)
87. Winder Ch. Best practice in workplace hazardous substances management. *Quality Assurance* 1995, 4(3): 211-225

88. Yeager AM, Kaizer H, Santos GW, Saral R, Colvin OM, Stuart RK, Braine HG, Burke PhJ, Ambinder RF, Burns WH, Fuller DJ, Davis JM, Karp JE, Stratford May W, Rowley SD, Sensenbrenner LL, Vogelsang GB, Wingard JR. Autologous bone marrow transplantation in patients with acute nonlymphocytic leukemia, using ex vivo marrow treatment with 4-hydroperoxycyclophosphamide. *NEJM* 1986, 315(3): 141-147
89. Zander AR, Culbert St, Jagannath S, Spitzer G, Keating M, Larry N, Cockerill K, Hester J, Horwitz L, Vellekoop L, Swan F, McCredie K, Dicke KA. High-dose cyclophosphamide, BCNU, and VP-16 (CBV) as a conditioning regimen for allogeneic bone marrow transplantation for patients with acute leukemia. *Cancer* 1987, 59(6): 1083-1086

PART III: CONSUMER INFORMATION

Pr PROCYTOX
(Cyclophosphamide tablets, USP)
(Cyclophosphamide for injection)

This leaflet is part III of a three-part "Product Monograph" published when PROCYTOX was approved for sale in Canada and is designed specifically for Consumers. This leaflet is a summary and will not tell you everything about PROCYTOX. Contact your doctor or pharmacist if you have any questions about the drug.

ABOUT THIS MEDICATION

What the medication is used for:

PROCYTOX (Cyclophosphamide) can be used alone or in combination with other medication to treat:

- Malignant lymphomas
- Multiple Myelomas
- Leukemias
- Mycosis Fungoides (Advanced disease)
- Neuroblastoma (in patients with disseminated disease, Stage IV)
- Carcinoma of the Breast (Stages II-IV)
- Retinoblastoma (St. Jude Stages II-IV)
- Malignant neoplasms of the lung

What it does:

Cyclophosphamide interferes with the growth of cancer cells by slowing their growth and spread in the body. Cyclophosphamide may also affect the growth of normal body cells. This could lead to undesirable side effects.

When it should not be used:

PROCYTOX should not be used if you have:

- allergy to Cyclophosphamide
- obstruction to urine flow manifested as difficulty with urination
- severe suppression of bone marrow function
- severe kidney problems
- severe liver problems
- active infection/suppressed immune system

What the medicinal ingredient is:

Cyclophosphamide

What the important nonmedicinal ingredients are:

Tablets: Calcium carbonate, Dibasic Calcium phosphate, Cellulose, Gelatin, Glycerin, Lactose, Magnesium stearate, Polyethylene glycol, Polysorbate, Povidone, Silicon dioxide, Starch (Corn), Sucrose, Talc, Titanium dioxide, Wax.

Injection: There are no nonmedicinal ingredients

What dosage forms it comes in:

PROCYTOX is available as a sterile powder for injection supplied in 20 mL, 50 mL, 75 mL, and 100 mL vials. It is also

available as 25 mg and 50 mg tablets.

WARNINGS AND PRECAUTIONS

Serious Warnings and Precautions
PROCYTOX should only be used under supervision of a doctor who is experienced in the use of anti-cancer drugs. Serious side effects that may occur with PROCYTOX include:

- Causing other types of cancers with long term use;
- Cardiac toxicity;
- Severe QT/QTc prolongation (disturbances in heart rhythm);
- Lung injury;
- Liver injury;
- Increased kidney and bladder injury;
- Serious allergic reaction;
- Vaccine induced infection when used in patients who have received live-vaccine

PROCYTOX can affect depolarizing muscle relaxants such as succinylcholine.

PROCYTOX should not be given to patients with low white blood cell and platelet count.

BEFORE you use PROCYTOX talk to your doctor or pharmacist if:

- You have any of the following conditions:
 - Previously received radiation therapy;
 - QT/QTc prolongation or family history of QT/QTc prolongation;
 - Electrolyte problems or conditions that could lead to electrolyte disturbances;
 - Cancer that has spread to the brain;
 - Low white blood cell count;
 - Low platelet count;
 - Low red blood cell count;
 - Cancer that has spread to the bone marrow;
 - Liver problems;
 - Kidney problems;
 - Difficulty urinating;
 - Cystitis (bladder infection);
 - Active infections;
 - Abnormal serum creatinine;
- You have had surgery in the previous 10 days, or have any upcoming surgery, including dental surgery; PROCYTOX may prevent normal wound healing.
- You are going to receive any vaccine.
- You are pregnant or likely to become pregnant or are nursing a baby.
- You are male and are likely to father a child.
- You have any allergies to this drug or its ingredients, including lactose or have lactose intolerance. PROCYTOX tablet contains lactose.
- PROCYTOX is not recommended for use in patients under 16 years of age.
- PROCYTOX may cause harm to an unborn baby. Female patients should use an effective birth control

method while using PROCYTOX. Male patients should not father a child while using PROCYTOX and for at least 6 months after the last dose of PROCYTOX.

- PROCYTOX may cause sterility in both male and female patients.
- Do not breast feed while taking PROCYTOX, the drug can get into the breast milk, and therefore, into the baby.

INTERACTIONS WITH THIS MEDICATION

Before and while taking PROCYTOX you should tell your doctor or pharmacist about your other prescription and non-prescription medications, vitamins, nutritional supplements and herbal products you are taking or plan to take.

This list shows some of the drugs (and their common use) and some procedures that may interact with PROCYTOX. Many medications may interact with PROCYTOX, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list.

- Alcohol
- Antibiotics (eg. ciprofloxacin, metronidazole, rifampin, chloramphenicol, sulfonamides)
- Anticoagulants such as warfarin (Coumadin)
- Antidepressants (eg. St. John's wort, bupropion)
- Anti-fungals (fluconazole, itraconazole)
- Cimetidine (for acid reduction)
- Corticosteroids such as prednisone
- Medications to aid in the management of selected chronic alcohol patients (disulfiram)
- Medications to treat rheumatoid arthritis (etanercept, indomethacin)
- Lovastatin (for high cholesterol)
- Medications to treat gout (allopurinol)
- Medications to treat seizures (eg. phenytoin, carbamazepine, phenobarbital)
- Medications to treat high blood pressure such as ACE inhibitors and thiazide diuretics (e.g. hydrochlorothiazide)
- Medications to treat heart problems and abnormal heart rhythm (eg. amiodarone, digoxin, prasugrel, verapamil)
- Medications to prevent vomiting (eg. aprepitant, ondansetron)
- Medications to stimulate the bone marrow (eg. G-CSF, GM-CSF)
- Medications to treat cancers (e.g. busulfan, tamoxifen)
- Medications that modulate immune system (eg. cyclosporine, azathioprine, methotrexate)
- Sedatives (eg. chloral hydrate, benzodiazepines)
- Medications to treat diabetes (sulfonylureas)
- Medications to treat HIV (protease inhibitors, zidovudine)
- Vaccines, especially live-vaccines
- Previous irradiation of the cardiac region

PROPER USE OF THIS MEDICATION

Your doctor will determine what dose of PROCYTOX is right for you and how often you should receive it. PROCYTOX tablet is to be taken by mouth.

PROCYTOX injection is to be given into the vein. It is important to drink extra fluids to help prevent kidney and bladder problems. Do not eat grapefruit or drink grapefruit juice while taking PROCYTOX.

Overdose:

In case of drug overdose, contact a health care practitioner, hospital emergency department or regional Poison Control Centre immediately, even if there are no symptoms.

Missed Dose:

If you miss your scheduled treatment, contact your doctor or nurse as soon as possible to schedule your next treatment.

SIDE EFFECTS AND WHAT TO DO ABOUT THEM

Cyclophosphamide can sometimes cause side effects such as blood problems, loss of hair, and problems with the bladder. Also, because of the way the drug acts on the body, there is a chance that it might cause other unwanted effects that may not occur until months or years later. These may include certain types of cancer, such as leukemia. Discuss these possible effects with your doctor.

SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM

Symptom / effect		Talk with your doctor or pharmacist		Stop taking drug and call your doctor or pharmacist
		Only if severe	In all cases	
Common	Anemia		√	
	Blood in Urine		√	
	Central Nervous System Troubles*		√	
	Fever or fever with low white cell count		√	
	Infection		√	
	Kidney problems		√	
	Liver problems		√	
	Loss of Appetite		√	
	Loss of Hair	√		
	Low platelet count		√	
	Low white cell count		√	
	Nausea/ Vomiting		√	

SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM

Symptom / effect	Talk with your doctor or pharmacist		Stop taking drug and call your
Urinary problems		✓	
Vein inflammation		✓	
Uncommon	Diarrhea		✓
	Fatigue	✓	
	Heart troubles		✓
	Low blood pressure		✓
	Malaise	✓	
	Mouth inflammation		✓
	Papular rash		✓
	Peripheral neuropathy**		✓
	Skin inflammation		✓

* For example Dizziness, Confusion, Convulsions, Headache

** For example, numbness of the hands and feet.

This is not a complete list of side effects. For any unexpected effects while taking PROCYTOX, contact your doctor or pharmacist.

HOW TO STORE IT

Store at temperature 15 °C – 25 °C. Protect from direct light.

REPORTING SUSPECTED SIDE EFFECTS

You can report any suspected adverse reactions associated with the use of health products to the Canada Vigilance Program by one of the following 3 ways:

Report online at www.healthcanada.gc.ca/medeffect
Call toll-free at 1-866-234-2345

Complete a Canada Vigilance Reporting Form and:

- Fax toll-free to 1-866-678-6789, or

- Mail to: Canada Vigilance Program
Health Canada
Postal Locator 0701D
Ottawa, Ontario
K1A 0K9

Postage paid labels, Canada Vigilance Reporting Form and the adverse reaction reporting guidelines are available on the MedEffect™ Canada Web site at www.healthcanada.gc.ca/medeffect.

NOTE: Should you require information related to the management of side effects, contact your health professional. The Canada Vigilance Program does not provide medical advice.

MORE INFORMATION

This document plus the full product monograph, prepared for health professionals can be obtained by contacting the sponsor, Baxter Corporation, at:

1-800-387-8399

This leaflet was prepared by Baxter Corporation.

Last revised: September 7, 2012